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This thesis examines the value of immunological
methods in the treatment, diagnosis and assessment of
prognosis of lung cancer.
Delayed hypersensitivity skin tests and laboratory
tests of immunological function were performed in patients
with operable lung cancer who were then randomly allocated
to the autograft or non-autograft groups. In a pilot trial
in 15 patients, the autograft group received intradermal
injections of autologous irradiated tumour cells and BCG.
during three weeks after operation. In this trial only,
both groups of patients were given radiotherapy to the
mediastinum three weeks after operation. In the subsequent
main trial in 83 patients, both groups received one pre¬
operative percutaneous injection of BCG.. The autograft
group only were given serial injections of autologous
irradiated tumour cells and percutaneous BCG. during the
three weeks after operation.
While the prevalence of positive tuberculin tests
among the lung cancer patients before operation was
similar to that of controls, sensitisation after challenge
by DNCB. was less common in the lung cancer patients,
suggesting that there is some impairment of the afferent
limb of the immunological response in this condition.
Lymphocyte transformation by PPD. but not PHA. or pokeweed
mitogen was depressed. Relative depression of certain
immunological tests was seen in patients with more advanced
disease and a poorer prognosis (total lymphocytes, DNCB.
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reactivity) and in squamous cell carcinoma (tuberculin
test). The main immunological effect of postoperative
immunotherapy was a prolonged increase in tuberculin
reactivity.
By constructing actuarial life table curves for
survival and duration of freedom from tumour recurrence
and by measuring the median times for these, it was shown
that DNCB. positive autograft group patients and those with
stage I tumours had better clinical results than non-auto-
graft patients (p = 0.02 to p = 0.09)« Although a higher
proportion of stage I patients in the autograft group
survived free of tumour recurrence two years after operation,
the difference was not statistically significant. Adjuvant
specific autologous immunotherapy thus seemed, at best, to
have only a weak therapeutic action in operable lung cancer.
In a separate study, circulating levels of tumour
markers in unselected lung cancer patients were compared
with those of control patients with benign pulmonary
disease. Elevated levels of carcinoembryonic antigen (CEA.)
were found in 17%» of pregnancy-associated a^-glycoprotein
(a^-PAG.) in 16%, of casein in 1 b°/o, of human chorionic
gonadotrophin in 6°/o and of a-foetoprotein in 1.5%• CEA.
levels were higher in patients with extensive disease (23%) •
There was discordance between raised levels of CEA. and
a^-PAG.. Elevated levels of one or more markers were found
in kG'/o of patients in whom four or more markers were
measured. In a different series of unselected lung cancer
patients, circulating levels of immunoreactive ACTH. were
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raised in 2k°/o of patients with small cell carcinoma but
only in 3°/° of patients with non-small cell carcinoma.
Elevated levels were commoner in small cell carcinoma
patients with extensive disease.
The results showed that when the upper limit of "normal"
was that of patients with benign pulmonary disease, the
prevalence of elevated levels of tumour markers was much
lower than that claimed by other authors. Hence measure¬
ment of these markers is of little or no diagnostic value
in lung cancer.
k
IMMUNOLOGICAL INVESTIGATIONS AND IMMUNOTHERAPY IN LUNG CANCER
Introduction
During the past 10 years, I have been a member of a
team of medical scientists who have been active in research
on lung cancer (the West of Scotland Lung Cancer Group).
As a clinical member, I have been closely involved in a
number of immunological investigations into the diagnosis
and treatment of this condition. This thesis is an attempt
to summarise this work and to combine our experience with
that of other workers in order to describe the present state
of knowledge in this interesting and expanding field.
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CHAPTER 1
EVIDENCE OF IMMUNOLOGICAL DEFENCE AGAINST CANCER
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The use of immunological techniques in the diagnosis
and treatment of cancer is based on the belief that there
is a host defence mechanism against tumours and that this
includes the production of antibody and the activation of
specialised immunological cells. The reasons for this
belief can be summarised under the following headings:
1. Variable progress and occasional spontaneous regression
Clinical experience has shown that histologically
similar tumours have widely varying growth rates in
different individuals. This has recently been confirmed
by Geddes (1979) who measured tumour doubling times in
patients with bronchial carcinoma. Occasional spontaneous
regression of histologically proven tumours has been reported.
For example, Everson and Cole (1956) described this occurrence
in kj patients collected from the literature during this
century. They included one case of lung cancer (Blades
and McCorkle, 195^)* Moreover the occurrence of metastases
many years after successful treatment of a primary carcinoma
is an occasional feature of some tumours e.g. breast
(Stewart 1952). This would suggest that cells deposited
in a distant organ at or before the time of operation can
remain there over years prevented from further growth by
the host defence mechanism. In this context we should
also add the poor relationship between the pathologist's
estimate of "grade of malignancy" and the clinical course
of cancer (Southam, i960).
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2. "Cure" following incomplete removal of tumour
Surgeons are sometimes surprised to find that patients
in whom only palliative resection of tumour has been
achieved live indefinitely without further progress of
tumour. This has been described in gynaecological tumours
by Graham and Graham (1955) and in lung cancer by Abbey
Smith (1970). This would suggest that natural defence
mechanisms are capable of eliminating small populations
of cells from the body. That this mechanism may be
immunological in nature is suggested by the occurrence of
tumours in patients who are taking immunosuppressive drugs
e.g. following kidney transplantation (Penn, 1978)* These
drugs may depress the immunological surveillance mechanism
so preventing the recognition of small numbers of tumour
cells as foreign.
3• Invasion of tumours by cells normally immunologically
active
Invasion of tumour tissue by lymphocytes, plasma cells
and macrophages has been widely reported. In general
these cells are more abundant in well differentiated
lung cancers than in small cell carcinomas and may be
seen in relation to destroyed tumour cells (loachim,
Dorsett and Paluch, 1976). Plasma cells are especially
numerous in squamous cell carcinoma.
Immunology of Lung Cancer
Immunotherapy is based on the belief that there is
an immunological defence against tumours and this can be
increased by immunotherapeutic procedures. Before discussion
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of immunotherapy in lung cancer, it is necessary to
consider the evidence that this tumour can evoke an immuno¬
logical response. This evidence can be summarised under
the following headings:
1. Existence of lung cancer associated antigens.
2. Circulating antibodies to these antigens.
3. Immune complexes.
k. Relationship between active cell-mediated immunity and
prognosis.
1. Lung Cancer Associated Antigens
In order to demonstrate the existence of tumour-
associated antigens in lung cancer, antisera have been
prepared by injecting 1.3 - 3M KC1 extracts of tumours
into laboratory animals (Frost, Rogers and Bagshawe, 1975)*
These antisera have then been absorbed with normal lung
and other body tissue components. Precipitin formation
after double immunodiffusion in agarose or, alternatively,
indirect immunofluorescence in tissue sections (Bell and
Seetharam, 1976) have been used to detect the presence
of antigen.
A variation of this method is the active immunisation
of rabbits with extracts of human lung cancer together
with rabbit antibody raised against normal human lung
extract. The latter step inhibits formation of antibodies
against normal human lung tissue. After a single absorption
with normal lung tissue extract, the antigen obtained is




Antigens of molecular weight between 40 and 200 x 10
daltons have been isolated (Braatz, Mclntire, Princler
et al« 1978; Gennings, Leake and Bagshawe, 1979)* One
antigen isolated had a sedimentation coefficient of 7S
and an electrophoretic mobility in the Pg globulin range
(Sega, Citro and Natali, 1979)* Glycoproteins and lipo¬
proteins have been among the antigens described.
It is well known that antigens to which animals are
exposed before or shortly after birth can suppress any
future reaction to such antigens when the immunological
system has reached maturity (Burnet and Fenner, 19^9)•
The fact that human cancer cells, including those of lung
cancer, carry antigens which also react with antisera
raised against foetal antigens may explain why the immuno¬
logical defence against these cells is ineffective. Watson,
Smith and Levy (1975) described two antigenic components of
lung cancer. Antiserum to the first reacted with normal
foetal lung and had relatively low cross reactivity with
histologically similar tumours. Antiserum to the second
did not react with foetal lung but had higher cross
reactivity with tumours of the same and other histological
types. Ford and Newman (1979) found that antiserum raised
against small cell carcinoma also identified antigens
present in normal and foetal lung tissue. Hollinshead
and Stewart (1977) identified as many as 5 antigens on
squamous cell carcinoma, k of which cross-reacted with
foetal tissue. There is thus antigenic similarity between
immature tissues whether they be foetal or neoplastic.
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Antiserum against one histological type of lung
cancer will react with extracts of other histological
types and even with extracts of tumours of other organs,
though with less frequency (Kelly and Levy, 1977)- However,
while cross—reactivity between squamous cell carcinoma
and adenocarcinoma is common, antisera raised against
plasma membrane antigen of small cell carcinoma do not
react with extracts of other histological types (Bell and
Seetharam, 1976). More recently the National Cancer
Institute group, using affinity chromatography and poly-
acrylamide gel electrophoresis^have isolated a highly
specific human lung tumour-associated antigen. Tumour
extracts from 85% of lung cancer patients but only 8°/o of
patients with other carcinomas gave a positive reaction
(Herberman, Mclntire, Braatz et al., 1978)* Using enzyme-
linked immunoassay (ELISA) Kelly and Levy (1980) were able
to show that sera from stage I lung cancer cases inhibited
the interaction of specific antitumour antibody with human
tumour-associated antigen preparations. Normal control
sera did not inhibit the interaction.
Most tumour-associated antigens described are surface
antigens and can be isolated from cultures of lung cancer
cells (Cerni and Micksche, 1976) and from malignant pleural
effusions (Cannon, McCoy, Dean et al., 1977; Herberman
et al., 1978). There is also indirect evidence of tumour
antigens in thoracic duct lymph (Han and Takita, 1976).
Extracts of autologous and allogeneic tumour tissue
(Bcddie, Holmes, Roth and Morton, 1975)> and cell culture
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lines of squamous cell carcinoma and malignant pleural
effusions (McCoy, Jerome, Cannon et al., 1977) can inhibit
migration of peripheral blood leucocytes from lung cancer
patients. This effect is not specific for leucocytes
taken from patients with the same histological type of
lung cancer and does not vary with the stage of the tumour
(Cannon et al., 1977)* It can be enhanced by washing the
leucocytes to remove adherent "blocking factors",
(Marabella, Takita, Takada and Minowada, 1975)*
Plasma membrane fractions of different histological
types of lung cancer have been shown to inhibit adherence
of leucocytes from patients with lung cancer. This occurred
in 80°/o of patients with the same histological type of tumour,
2h°/o of patients with lung tumours of different histology
but in only 1 k°/o of patients with other chest diseases
(Anthony and Millband, 1978).
Tumour extracts can also stimulate protein synthesis
in lymphocytes from lung cancer patients (Roth, Holmes,
Boddie and Morton, 1975) and can inhibit mitogen-induced
transformation of lymphocytes from normal donors (Roth,
Chee, Morton and Holmes, 1978).
Serum from lung cancer patients also inhibits
migration of peripheral blood leucocytes and blocks
mitogen-induced transformation of lymphocytes. The latter
has been shown using normal lymphocytes from human donors
(Roth et al., 1978); and rabbit mononuclear cells stimul¬
ated by bacterial extracts (Kubickova, Kubin, Svejcar,
et al., 1979).
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Although, the exact factors responsible for the
inhibitory action of lung cancer serum is not known with
certainty, they may include tumour antigens. While these
may be bound in immune complexes in the serum, the inhibitory
action of tumour extracts and thoracic duct lymph suggest
that immune complex formation is not essential for
inhibition.
2. Antibodies: presence in lung tumour tissue and the
circulation
There are relatively few reports of the presence of
antibodies in host tumour tissue. This may be because
they are produced intermittently in small amounts or
because they are combined in antigen-antibody complexes
(Paluch and Ioachim, 1978). Low antibody production may
arise because the antibody-producing cells are inhibited
by tumour factors or because tumour antigen evokes only a
cellular response (Kennel, 1979)*
Antibodies to lung cancer cells have been demonstrated
in serum, tumour extracts, malignant pleural effusions and
bronchial washings but only infrequently and with great
difficulty. In an attempt to demonstrate antitumour anti¬
bodies in serum from lung cancer patients, Takada, Takita
and Marabella (1976) added test serum to cultured cells
from allogeneic small cell carcinoma and adenocarcinoma
of lung and from carcinoma of the cervix. The cells were
then stained using an immunofluorescent technique.
Evidence of antitumour antibody was found in serum from
only one of 26 patients. Complement-dependent cytotoxic
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antibody was found in sera from 3/l8 patients by Dawson
and Moore (1975)* Sera from 8/l8 patients induced
cellular cytotoxicity in leucocytes from healthy donors.
The same authors found that lung cancer patients' sera
showed blocking activity against allogeneic leucocytes
from lung cancer patients. Using an indirect immuno-
fluorescent technique Gorny, Jezewska, Krzysko et al.
(1979) detected antibody against allogeneic squamous cells
in culture in 22%,against autologous cultured cells in 50%
and against autologous and allogeneic fresh squamous
carcinoma cells in 66% of sera from lung cancer patients.
They found that these sera contained specific IgM anti¬
bodies against surface antigens.
Antibodies have been detected in tumour tissue by
Paluch and Ioachim (1978). Acid eluates from minced
squamous cell and adenocarcinoma tissue were found by
radial immunodiffusion to contain mainly IgG with small
amounts of IgA and IgM. Eluates from small cell carcinoma
contained minimal amounts of IgG but no IgA or IgM.
Immunoglobulins eluted from tumour tissue and pleural
effusions of squamous cell carcinoma and adenocarcinoma
were shown by immunofluorescence to react with tissue
cultures and suspensions of cells of the same histological
types. This evidence that immunological activity is
greater against squamous cell carcinomas and adenocarcinoma
than against small cell carcinoma supported the observation
of the same workers that a local mononuclear cell reaction
is a feature of squamous cell carcinoma and adenocarcinoma
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rather than of undifferentiated carcinomas (loachim,
Dorsett and Paluch, 1976).
B lymphocytes are the progenitors of the different¬
iating line of cells whose mature member is the plasma
cell. Increased numbers of B lymphocytes have been found
in patients with squamous cell carcinoma that has spread
to local lymph nodes, (Ritts, Jacobson, Caron et al., 1977)•
A relative increase of circulating B cells also occurred
with tumour progression (Anthony, Kirk, Madsen et al.,
1975)* However, increase in B cell concentrations in the
circulation has not been widely reported in lung cancer.
As all antibodies are immunoglobulins, changes in
the serum levels of these might give some clue to the
ability of the humoral defence mechanism to resist tumour
cells. Plesnicar and Rudolf (1979) found that survival
times of patients with lung cancer were longest when the
levels of individual serum immunoglobulins fell within a
narrow range towards the upper limit of normal.
It may thus be that there is an optimum level of
circulating antibody. Below this level, the circulating
antibody is insufficient to neutralise tumour antigen.
Above it, excess antibody blocks the antitumour activity
of immunocompetent cells. However other factors, e.g.
the distribution of surface antigen receptors on the




In 1971, Sj&'gren, Hellstrttm, Bansal and HellstrOm
reported that sera from mice bearing experimentally in¬
duced sarcomas blocked the cytotoxic effect of lymphocytes
immune to the relevant tumour specific antigen. This
blocking factor consisted of two components, one of high
and one of low molecular weight, neither of which had
blocking activity in a standard test by itself. They
postulated that the blocking activity was due to circulating
antibody-antigen complexes.
In an extensive review of circulating immune complexes
in cancer, Baldwin and Robins (1980) classified methods of
measuring these into four groups:
Physical separation of complexes
Interactions with complement e.g. Clq binding
Interactions with rheumatoid factors
Interactions with cells e.g. Raji cell binding and
Staphylococcus aureus binding.
Tests of Clq binding measure complement binding immune
complexes whereas the Raji cell and the Staphy1ococcus
aureus binding technique measure both complement and
non-complement binding immune complexes.
Circulating immune complexes in cancer have sediment¬
ation coefficients between 10 and 30 S and can be dissociated
at low pH into IgG fractions reacting in membrane immuno¬
fluorescence tests with tissue culture cells (Paluch and
Ioachim, 1978).
Using Raji cells, a human lymphoblastoid cell line
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with B cell characteristics, Theofilopoulos, Wilson and
Dixon (1976) demonstrated circulating immune complexes
in 2 of 7 lung cancer patients tested. Evidence of
circulating immune complexes using the Clq binding assay-
was found in 90°/o lung cancer patients by Rossen, Reisberg,
Hersh and Gutterman (1977) and in 67% by Heier, Carpentier,
Lange et al. (l977)» However, using the same technique,
Lowe, Segal-Eiras, lies and Baldwin (1981) found increased
Clq binding activity in only 3^°/° of lung cancer patients
and in as many as 20°/o of age and sex matched controls.
There was no significant difference in mean values between
patients and controls although the highest levels were
seen in the lung cancer patients. Absence of correlation
with total wbc. count and ESR, was taken to indicate that
increased Clq binding activity was not due to infection.
This is a questionable assumption as neither of these
are very reliable guides to infection in lung cancer; the
wbc. can be considerably elevated in patients with rapidly
growing tumours in the absence of infection. Serum Clq
binding activity was not related to histological type
or survival but did correlate with the extent of malignant
disease. This confirmed the finding of Jansen, The, de
Gast et al., (1977) who also found a higher level of
circulating immune complexes in patients with large and
small cell undifferentiated carcinomas.
More recently, Guy, di Mario, Irvine et al. (198I)
found elevated serum Clq binding (solid phase) in only
13°/° of lung cancer patients compared with 10°/o of normal
blood donors and 6°/o of bronchitic patients. Using the
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Raji cell and Staphylococcus aureus binding techniques,
these authors found elevated levels in kk°/c and 33°/°
respectively of lung cancer patients compared with 50%
and bb°/o of bronchitic patients. Although bronchitic
patients with active infection were excluded,previous
infection may well have been a factor in causing elevated
levels in both groups of patients. Indeed these authors
found no evidence that immune complexes in lung cancer
patients contained a tumour specific antigen component.
Measurement of immune complexes by existing techniques
is of little or no diagnostic value but it might prove
useful in monitoring progress of the disease and the
response to therapy (Lowe et al., 1981).
k. Immunological reactivity and prognosis
One of the earliest discoveries during the investigation
of immunological changes in lung cancer was that patients
with positive delayed hypersensitivity skin (DHS.) tests
and/or active cell-mediated immunity survived longer than
those without. Patients with positive delayed hyper¬
sensitivity skin reactions to tuberculin (Israel, Bouvrain,
Cros-Decam and Mugica, 1968) and dinitrochlorobenzene
(DNCB.) (Krant, Manskopf, Brandrup and Madoff, 1968) had
significantly greater survival times than negative reactors.
In addition, a higher proportion of patients with impaired
lymphocyte reactivity to phytohaemagglutinin (PHA.) died
within 2 months than of those with normal lymphocyte
reactivity (Han and Takita, 1972).
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The prognostic value of delayed hypersensitivity
skin reactions has since been confirmed for recall
antigens including tuberculin (Israel, Mugica and
Chahinian, 1973) and for new antigens including DNCB.
(inoue, Ishihara, Kobayashi, and Fukai, 1978; Liebler,
Concannon, Magovern et al., 1977)* Moreover, as T lymph¬
ocytes are an essential component of the cell-mediated
immunological reaction, the relationship between
circulating T cell levels and prognosis has been studied.
Stefani and Kerman (1979) found a linear relation between
total circulating T cells and survival. In the study of
Dellon, Potvin and Chretien (1979)> all patients with an
absolute T cell count less than 750/ml died or developed
metastases within 9 months. In contrast 55CZ> of patients
with pretreatment T cell levels more than 750/ml were
alive and free from tumour metastases 9 months after
treatment.
The position with lymphocyte reactivity to mitogens
is not so clear cut. Most other studies have confirmed
that normal lymphocyte reactivity is associated with a
better prognosis than depressed reactivity (Wanebo, Rao,
Miyazawa et al., 1976; Liebler et al., 1977; Giuliano,
Range1, Golub, et al., 1976). However, Barnes, Farmer,
Penhale et al. (1975) found no difference in survival
of patients with disseminated and anaplastic tumours
after operation between those with normal and those with
depressed lymphocyte reactivity to PHA. Similarly
Braeman and Deeley (1973) found no relationship between
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lymphocyte reactivity to PHA. and purified protein
derivative of tuberculin (PPD.) and survival after
irradiation of tumour cells. This discrepancy might be
explained by the combination of surgery and advanced
stage of the tumour in the first series and the long
standing depression of immunological activity by radio¬
therapy in the second.
Patients with strong delayed hypersensitivity skin
reactions and normal cell mediated immunity have a better
prognosis than those without; this suggests that lung
cancer evokes an immunological defensive response in the
host. However, there are 3 other possible explanations:
1. Cell-mediated immunological reactions are depressed
in proportion to the size and extent of tumour tissue.
2. Patients with normal immunological reactivity respond
better to treatment.
3» Malnutrition, a feature of more advanced cases,
depresses cell-mediated immunity.
Tests of delayed skin hypersensitivity and cell-mediated
immunity are depressed in patients with advanced tumours.
This has been shown for skin reactions to DNCB. (Vanebo
et al., 1976; Giuliano et al., 1979) and tumour extracts
(Weese, Herberman, Hollinshead et al♦, 1978), for absolute
numbers of circulating T cells (Shirakusa, Shigematsu
and Yoshida, 1978) and for lymphocyte responsiveness to
mitogens (Vanebo et al., 1976; Giuliano et al., 1979)-
If it were caused solely by factors released by the tumour,
depression of these tests in an individual might simply
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indicate that the tumour was advanced and likely to
cause death soon. However even in series of patients
with maximal tumour burdens such as the inoperable cases
of Han and Takita (1972) and the Stage 3 small cell
carcinoma cases of Jdnsen, Esselink, Orie and The (l979)>
active cell mediated immunity carried a relatively better
prognosis. Moreover, patients with metastases but normal
skin and laboratory tests had as good a prognosis as those
with localised disease but abnormal tests (Liebler et al.,
1977).
Patients with evidence of active cell-mediated immuni
respond better to chemotherapy (Pouillart, Schwarzenberg,
Huguenin et al., 1976) and radiotherapy (Stefani and
Kerman, 1979) and are more likely to have operable tumours
(inoue et al., 1978). However, even in patients who have
completed therapy, normal cell-mediated immunity carries
a better prognosis (Gross and Eddie-Quartey, 1976). Thus
response to treatment is not the only factor linking the
results of immunological tests with prognosis.
Malnutrition depresses delayed hypersensitivity skin
tests and cell-mediated immunity. As this is a late
feature in lung cancer, it would not account for the
association of depressed immunological reactivity with
a worse prognosis in patients with resectable tumours
(inoue et al., 1978).
It is thus evident that positive delayed hypersensiti
ity skin tests and active cell-mediated immunity indicate
that lung cancer can evoke an immunological response.
This response can help resistance to the progress of the
tumour and so increase survival.
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CHAPTER 2
IMMUNOLOGICAL MECHANISMS OF DEFENCE AGAINST TUMOUR CELLS
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In order to understand the possible role of immuno¬
therapy in lung cancer, we need to consider some of the
immunological mechanisms which may be involved in the
defence against tumour cells, why these have failed in
patients with established tumours and how this failure
might be corrected.
The principal cells involved in the response to
tumours are lymphocytes and macrophages and their roles
are summarised in Figure 1. Those cells which actually
damage tumour cells are:
1. Lymphocytes
(a) T lymphocytes
(b) Antibody-determined killer (k) cells
(c) Natural killer (NK) cells
2. Macrophage s
Lymphocyt e s
The ability of lymphocytes to damage tumour cells
has been shown in numerous studies of "cytotoxicity".
In these studies lymphocytes from peripheral blood are
added to cultured tumour cells. Cell viability can be
assessed by staining since killed cells stain with
trypan blue or crystal violet whereas living cells
exclude these dyes (Hellstr&m, Hellstrbm, Sjogren and
Warner, 1971; Konda and Smith, 1973)* Viability of
target cells can also be assessed by the release of
radioisotope with which they have been labelled or by
the uptake of certain vital metabolites labelled with
radioisotopes. Schecter, Treves and Feldman (1976)
3 3
showed decreased uptake of H leucine and II thymidine by
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target Lewis lung tumour cells from mice exposed to
autologous lymphocytes. More recently, Vose, Yanky,
Fopp and Klein (1978) found evidence of cytotoxicity
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against Cr-labelled autologous lung tumour cells in
peripheral blood lymphocytes from 15 of k'J patients with
lung cancer. Cytotoxicity against allogeneic lung cancer
and other cancers was rare.
Other indirect evidence of lymphocyte involvement has
come from in vivo studies. Konda and Smith (1973) observed
an increase in lymphocyte population of spleen and lymph
nodes of mice in whom methyl cholanthrene-induced sarcomas
had been produced. In humans Ioachim et al., (1976)
noted a marked infiltration of lymphocytes and plasma
cells in relation to destroyed tumour cells in lung
cancer tissue.
It is likely that at least some T lymphocytes are
cytotoxic to tumour cells. Konda and Smith (1973) found
increased T cells in their tumour bearing mice. Janik
and Szarniawska (1978) found that T lymphocytes were
necessary for restoration of immunity to transplanted
tumour in irradiated thymectomised mice. Using autologous
target cells from freshly prepared lung tumours, Vose
(1980) showed that in 9 of 21 patients where cytotoxicity
was demonstrated, the effector cells were mainly T cells.
Moreover Ramey, Ilashim, Munther et al. (1980) found
evidence of lung tumour antigen-sensitive T cells in
20/32 lung cancer patients.
ro •p-
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Pig. 1. Immunological mechanisms involved in the
defence against tumour cells. The diagram shows a
cancer cell (CC) coated with different antigens being
attacked by a cytotoxic lymphocyte, (Tc), an activated
macrophage (Ma), a killer cell with antibody receptors
(k), and a natural killer cell (nk). The stem T cell
(t) gives rise also to helper T cells (Th), helper cells
with receptors for IgM (Tm), and non-adherent suppressor
T cells which inhibit other lymphocytes (Ts). B cells
(b) lead to production of antibody (igG) attached to
antigen on the cancer cell surface.
Monocytes (Mo) aggregate under influence of monocyte
chemotactic factor (M.C.F.) and become activated under
influence of macrophage activating factor (M.A.F.).
They also form adherent suppressor cells (Ms) which
inhibit the cytotoxic action of T cells. Blocking
factors, possibly immune complexes, also have this
action.
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The role of killer (k) cells in lung cancer has
not yet been well defined. These are lymphocytes which
possess surface receptors for IgG and which are capable
of binding to and damaging tumour cells coated with this
immunoglobulin (Jonsdottir, Dillner-Centerlind, Perlmann
and Perlmann, 1979)* While some of these cells possess
T cell markers, others lack surface markers of B and T
cells and are therefore "null cells".
There has recently been considerable interest in
another group of cytotoxic lymphocytes, the natural killer
or NK cells (Herberman, Timonen, Ortaldo et al., I98O;
Mitchison and Kinlen, 1980). Most NK activity has been
found among large granular lymphocytes with indented
nuclei. NK cells make up 1 - 2°/o of all lymphoid cells
in spleen or peripheral blood. In vitro experiments have
shown that they are spontaneously cytolytic not only for
tumour cells but also for a variety of cells infected
by viruses. In vivo they increase the rate of clearance
of labelled tumour cells. NK cells have surface receptors
for IgG but IgG does not inhibit their killing ability.
The possession of some T cell surface markers suggests
that NK cells are related to the T lymphocyte series
but they do not form E-rosettes under the usual laboratory
conditions and are thus also "null cells". It is of
particular significance that NK cell activity is enhanced
by Bacille Calmette Guerin (BCG.) and Corynebacterium
parvum (C. parvum) (also by interferon) and that NK
activity decreases with age.
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As well as having a direct cytotoxic action, T
lymphocytes also act on two other groups of cells, B
lymphocytes and macrophages.
With the development of techniques using mouse mono¬
clonal antibodies it has become possible to identify two
contrasting subsets of T cells (janossy, Tidman, Selby
et al., 1980). Helper T cells (designated Tm cells because
they bear surface receptors for IgM) react with mouse
monoclonal antibody OKT^. They help B cell proliferation
and differentiation into plasma cells (Moretta, Mingari,
Moretta et al., 1980) and lymphocyte response to PHA.
and Con A. This helper activity is resistant to irradiation
but may be reduced in patients with stage 3 lung cancer
(jansen, The and Orie, 1979)- In contrast, suppressor T
cells (designated either Ts as in Fig. 1 or T^ because of
their surface receptors for IgG) react with mouse mono¬
clonal antibodies OKT_ and OKTQ. Their properties are
5 o
discussed on p.30.
Lymphocytes exposed to antigen and mitogen release
a number of factors which stimulate the monocyte/macro¬
phage system. These "lymphokines" include a macrophage
activating factor isolated from PPD. stimulated BCG.
immune mouse spleen cell culture fluids (Leonard, Ruco
and Meltzer, 1978). Lymphokines can enhance spreading,
phagocytosis and the chemotactic attraction of macro¬
phage s (qv) .
Macrophage s
The monocyte/macrophage system originates in bone
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marrow where monocytes mature before passing into the
peripheral circulation. Some of them later become
tissue macrophages.
It is uncertain whether the monocyte/macrophage
system responds directly to tumour antigen. Macrophages
carry Fc receptors so that tumour cells coated with
immunoglobulin can be expected to bind directly to them
(and possibly to produce activation) (Kjeldsberg and Pay,
1978). However indirect stimulation certainly does occur.
This is mainly effected by the release of lymphokines
from stimulated lymphocytes. These lymphocytes are the
probable source of monocyte chemotactic factor which
imparts directional mobility to monocytes and of macro¬
phage activating factor to which reference has already
been made. Monocyte chemotaxis has been measured in lung
cancer patients and found to be normal except in advanced
cases (McVie, Logan and Kay, 1977)• Macrophages may be
activated directly under experimental conditions by
injection of a variety of bacterial antigens including
BCG. and C. parvum.
Evidence that macrophages kill tumour cells comes
from animal experiments. For example macrophages have
been shown to be cytotoxic to mouse lymphoma cells in
culture (Evans and Alexander, 1972). Certain macrophage
activators such as Brucella abortus ether-extract (Schultz,
Pavlidis and Chirigos, 1978) reduced the development
of pulmonary metastases in mice in whom tumour cells
had been transplanted or injected intravenously. In
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contrast, macrophage poisons such as silica and cara-
geenan increased the growth of pulmonary metastases in
mice transplanted with an ovarian carcinoma (Mantovani,
Giavazzi and Polentarutti, 1980). In humans Muller and
Kolb (1979) found a marked infiltration of macrophages
within the septae and alveoli of patients with lung cancer.
Finally, adherent cells, principally macrophages, isolated
from lung tumours were found to be cytotoxic to autologous
tumour cells in 17 out of 25 cases by Vose (1978).
REASONS FOR FAILURE OF IMMUNOLOGICAL DEFENCE MECHANISM
With such a complex and varied defence against tumour
cells, why do tumours ever develop? Possible answers
can be considered under four headings:
1. Failure of recognition
2. Serum blocking factors
3. Suppressor cells
h. Intrinsic lymphocyte defects
It has been suggested that tumour cells are only
weakly antigenic and are not therefore recognised as
foreign. Evidence to the contrary has already been cited
for lung cancer from which numerous tumour-specific
antigens have been isolated. Coating of tumour cells by
antibody and/or immune complexes might also mask their
foreign nature. The fact that injected tumour cells
are rendered more immunogenic by neuraminidase which
removes coating sialic acid residues suggests that such
coating might also screen tumour cells from the immuno¬
logical surveillance mechanism in vivo.
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Reference has already been made to the blocking
factors in serum in connection with the inhibitory
action of serum from cancer bearing animals and with
immune complexes (page 15)• Serum from 67/8I cancer
patients blocked the cytotoxic effect of their lymphocytes
on autologous tumour cells and allogeneic tumour cells of
the same histological type (Hellstrttm, Sjttgren, Warner
and HellstrOm, 1971)• Another form of inhibitor present
in serum of cancer patients is monocyte chemotactic
factor inactivator. This has been described in 90°/o of
patients with lung and prostatic cancer using a chemo¬
tactic agent made from E. coli. In h^°/o of these monocyte
chemotaxis was defective. In 2/k lung cancer patients
undergoing surgical resection of tumour, this factor dis¬
appeared after operation (Kjeldsberg and Pay, 1978). In
contrast, depressed Fc receptor activity of pulmonary
alveolar macrophages has been attributed to local release
of a blocking factor by tumours (Rhodes, Plowman, Bishop
and Lipscomb, 1981).
Suppressor Cells
Suppressor cells inhibit cells or activities concerned
with the immunological defence mechanism. There are two
main type s:
(a) Adherent cells which are removed by passage through
Sephadex G 10 columns and which are believed to belong
to the monocyte/macrophage series.
(b) Non-adherent cells, a subpopulation of T lymphocytes,
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designated Ts cells whose properties have been extensively
reviewed by Gershon (1980). These Tg cells are character¬
ised by certain L surface antigens. There are different
subsets of Tg cells with varying abilities and properties.
Gershon and his colleagues postulated a suppressor cell
circuit with inducer, amplifier/precursor, amplifier
and effector cells. Ts cells suppress helper T cells,
B cells and macrophages and form part of a negative feed¬
back system which regulates the immunological defence
mechanism.
Suppressor cells were detected in 11/20 lung cancer
patients by Jerrells, Dean, Richardson and Herberman (1979)•
In 7/ll the suppressor cells were monocytes and 5 of these
7 had received BCG. immunotherapy. Ts cells are believed
to make up a significant proportion of the lymphocytes
which infiltrate lung tumour tissue (Vose and Moore,
1979).
Lymphocyte Deficiency
This project and a review of many investigations of
immunological function in lung cancer will show that
there are some abnormalities of cell-mediated immunity in
established lung cancer. Whether these are merely the
result of the existence of tumour cells or the cause of
the development of these cells is not known. Jerrells,
Dean and Herberman (1978) postulated that the abnormal
lymphocyte reactivity found in lung cancer patients with
normal counts of total lymphocytes and T cells may be due
to depletion of a specific subpopulation of T cells.
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This group of T cells formed rosettes at 29°C as well
as at b°C and were thus known as high affinity E-rosette
forming cells. It could thus be that depletion of
certain subpopulations of lymphocytes may play a part
in the development of lung cancer.
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CHAPTER 3
THE DEVELOPMENT OF IMMUNOTHERAPY IN LUNG CANCER
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(a) Use of tumour cells or extracts
Attempts to stimulate host defences against tumours
were first made at the end of the last century. The
impetus for these seems to have come from the concept
of immunity to infection and the development of active
immunisation against diseases such as smallpox. Despite
the enormous gulf between immunisation against future
infection and immunisation against established cancer,
some workers embarked on a series of immunological
experiments on animals and on humans with advanced cancer.
The animal experiments had an obvious defect in that
tumours under investigation were transplanted into wild,
randomly selected animals and not into the carefully sel¬
ected inbred species used in modern laboratories. Hence
tumour rejection, which at the time seemed promising, may
have been due to simple allograft tissue rejection rather
than specific antitumour resistance (Currie, 1972).
Many of the early investigations in humans involved
a form of specific active immunotherapy. Yon Leyden and
Blumenthal (1902) injected 2 patients with advanced
cancers of urethra and uterus and ovaries with filtrates
of their own tumour tissue and observed some reduction in
size of enlarged lymph nodes though no change in the over¬
all progress of their disease. During the next 50 years
sporadic similar investigations were carried out.
Assessment of the clinical effect of such treatment was
largely subjective and in few studies were prospective
controls used. In a few, some attempt was made to measure
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the immunological results of treatment. For example,
Yaughan (1914) observed that anticancer antiserum
raised in animals was clinically effective only when
its use was followed by an increase in circulating
mononuclear cells.
The majority of early attempts at specific immuno¬
therapy in humans were carried out on patients with
advanced tumours especially those involving breast and
gastrointestinal tract. As the first successful resection
of lung cancer did not occur until 1933 (Graham and
Singer, 1933) bronchial carcinoma never featured in
earlier studies of immunotherapy where autologous tumour
tissue was used. While a few cancer patients seem to have
derived some benefit from treatment (Vaughan, 1914) it
was ineffective in the majority. Side effects were
fortunately rare. In particular, local growth of tumour
at the site of injection of tumour cells was rare although
only Kellock, Chambers and Russ (1912) irradiated the
cells before injection. Enhancement of growth of the
primary tumour or metastases was also an infrequent
occurrence (Risley, 19H).
Between 1950 and i960, workers began to measure the
immunological effect of immunotherapy. Graham and Graham
(1955) prepared antigens from gynaecological tumours
removed at operation. They used these to demonstrate
antibodies to tumour antigen which were present in 12/48
patients. The same workers found a three fold rise in
serum gamma globulin in 6 of 35 patients treated with
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autologous tumour vaccines (Graham and Graham, 1959)*
Twenty-six out of 60 patients had a significant increase
in epithelial cells with densely staining finely vacuolated
cytoplasm in vaginal secretions. Their presence indicated
that the tumour was more likely to respond to radiotherapy.
Finney, Byers and Wilson (i960) measured serum antibody
levels in 9 patients treated with autologous tumour vaccine
in complete Freund's adjuvant, one of whom had a lung
cancer. The antibody levels rose to a plateau 30 days
after injection and remained at the same level for the
remaining 60 days of the study.
Some of the early animal trials of specific immuno¬
therapy were carried out at the Chester Beatty Research
Institute. For example, Haddow and Alexander (1964)
injected irradiated autologous tumour cells into rats
bearing benzpyrene-induced fibrosarcomas. This increased
tumour response to radiotherapy.
No adjuvant was used in most early studies of specific
active immunotherapy in cancer although Southam (i960)
commented on the illogicality of removing cancer tissue
from a patient and injecting it elsewhere in the same
patient unless it was rendered more immunogenic by purific¬
ation, concentration or addition of adjuvant.
Thus by 1970, the use of adjuvant in trials of
specific immunotherapy had become established. In the
much quoted investigations of Mathe', BCG. was found to
enhance the effect of irradiated autologous leukaemia cells
in delaying growth of L. 1210 leukaemia grafted into mice
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(Mathe', Pouillart and Lapeyraque et al. , 1969a) and a
similar form of immunotherapy was used with apparent
success in humans with acute lymphoblastic leukaemia
(Mathe', Amiel, Schwarzenberg et al. , 1969b).
(b) Bacterial antigens
The use of bacterial antigens to stimulate host
resistance to tumours started around the turn of the
century. Loeffler (l90l) described injection of staphylo¬
cocci and later tubercle bacilli in patients with advanced
cancer. Use of tubercle bacilli was suggested by the
observation that tuberculosis and cancer rarely occurred
in the same patient. McCaskey (1902) found that less
than 2°fo of 281 patients dying with cancer had autopsy
evidence of tuberculosis. Pearl (1929) found active
tuberculosis in 6.6^ of 8l6 patients with malignant growths
compared with 16.3% of patients free of cancer. These
observations were in agreement with the epidemiological
discovery that the fall in incidence of tuberculosis
between I89I and 1911 was paralleled by a rise in incidence
of cancer (Cherry, 1924).
After the second world war, there was renewed interest
in bacterial antigens as anticancer agents. BCG. vaccination
had been introduced for the prevention of tuberculosis in
1921 (Calmette and Gu^rin, 1924). In 1959> Halpern, Biozzi,
Stiffel et al. described retardation of the growth of
injected tumour in rats by intravenous BCG. and the Grahams
reported on the use of complete Freund's adjuvant
(Myobacterium hominis in mineral oil suspension) in
patients with advanced cancers, (Graham and Graham, 1959)*
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Corynebacterium parvum, an anaerobic organism, was
found by the French group to stimulate the reticulo¬
endothelial system of mice (Halpern, Prdvot, Biozzi
et al., 1964). Injection of the same organism into these
animals 2 days before and between 8 and 12 days after
subcutaneous inoculation of viable mammary carcinoma
delayed the growth of the implanted tumour (Woodruff and
Boak, 1966). Thus mycobacterial antigens and C. parvum
were available as single agents or as adjuvants at the
start of the great immunological attack on lung cancer
which started after 1965*
(c) Immunotherapy in lung cancer
Methods of immunotherapy used in lung cancer are
summarised in Figure 2 (from Stack, 1980). Most of the
early work involved the use of non-specific methods.
These consisted of introducing agents which cause a general
stimulation of all cells concerned with the immunological
response in the hope that some of the activated immuno¬
competent cells would attack the tumour cells. Bacterial
antigens have been much the most popular stimulants of
non-specific immunity and the majority of these have been
mycobacteria or extracts of these organisms.
Most of the early trials of non-specific immunotherapy
in lung cancer were carried out in patients with advanced
disease. For example, Hadziev and Kavaklieva-Dimitrova
(1969) treated 71 patients with stages 3 and k lung
cancer with intradermal BCG. and found increased mean
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survival compared with controls. Israel (197^-) found
that combination of Corynebacteria (parvum or granulosum)
with chemotherapy produced better survival of inoperable
cases than chemotherapy alone.
In one of the earliest prospective trials in operable
cases, Edwards and Whitwell (197^+) found initial promising
results from post-operative subdermal BCG. Only a single,
relatively low dose was given and this early promise was
not confirmed in subsequent reports (Edwards and Whitwell,
1978).
Immunorestorants are drugs or extracts which restore
depressed cell-mediated immunity to normal. They might
thus be expected to be of value during the post-operative
period when immunological function is depressed (see later).
An early report of the use of levamisole suggested that it
might be a valuable adjuvant to surgery in operable cases
(Study group for bronchogenic carcinoma, 1975)* However
these results have since been confirmed only for patients
in whom the dose of levamisole exceeded 2.1 mg/Kg (Amery,
1980). Use of this drug was associated with an excess
death rate from cardiorespiratory failure in one series
(Anthony, Mearns, Mason et al., 1979)*
Passive immunisation has not been widely employed.
Newman, Ford, Davies and O'Neill (1977) gave intravenous anti¬
serum raised against tumour cells in goats to some patients
receiving chemotherapy after resection of bronchial carcin¬
oma. Although there were more deaths and tumour recurrence
among the controls, the difference was not significant.
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Specific immunotherapy involving the injection of
lung tumour cells or extracts was also tried on inoperable
cases initially. Takita and Brugarolas (1973) used
autologous tumour cells, antigenic protein and complete
Freund's adjuvant, and Tallberg (1974) administered polymer
particles coated with autologous tumour extract. The early
results suggested that such treatment might be beneficial
and it was on this basis that the West of Scotland Lung






Preliminary details of this trial were given by Stack,
McSwan, Stirling et al. (1979)• Informed consent for the
investigation was obtained from patients undergoing
thoracotomy for suspected bronchial carcinoma at the
Regional Cardiothoracic Centre, Mearnskirk Hospital,
between November 1st 1975 and May 1st 1976. In order to
obtain randomly selected comparable groups, a series of
cards were prepared which were divided between male and
female and between the age groups less than kO, k0-k9,
and 50-69* At the time of operation, once the surgeon had
decided that the tumour was resectable, a telephone call
was made to the clerical assistant who then randomly
selected an envelope containing one of the cards. This
allocated the patient to the autograft or non-autograft
group.
Preparation and injection of tumour cell suspension
The excised tumour was transected and a 0.5 cm cube
of solid tumours macroscopically free from fat and necrosis,
was excised and placed on a 100-mesh stainless steel
gauze (Anderson, Kelly, Wood et al., 1973)* The tissue
was diced into small pieces with scalpels and then ground
down using a glass pestle. The material was then washed
through the gauze using 20 mis of Eagle's medium (a
balanced salt solution containing penicillin, strepto¬
mycin and antimycotic agents). The resulting suspension,
which was about 20 mis in volume, was placed in a
sterile plain glass container. No further antibiotics
and no enzymes were added. This container was transferred
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immediately to the Radiotherapy Department of Belvidere
Hospital for irradiation.
Irradiation of the tumour cell suspension was achieved
by using a special applicator which allowed the cell
containers to be placed as near as possible to the source
of radiation. A minimum dose of 12,250 rads x-ray therapy
(half value layer 2.5 mm.cu.) was delivered to the cells
in a single dose. Occasionally super voltage irradiation
was employed, a dose of 1^1-, 280 rads being delivered to
obtain the same biological effect.
After irradiation the tumour cell suspension was
divided between 5 or 6 tubes, each tube containing 1.5 mis
of suspension.
Provided that the diagnosis of lung cancer had been
confirmed by a frozen section taken at the time of operation,
two tubes containing 3 mis of tumour cell suspension were
returned to the Cardiothoracic Unit and the remainder was
despatched to the laboratory where it was quenched in
liquid nitrogen at -210°C. A small proportion however
was injected onto two blood agar plates in order to detect
contamination with aerobic organisms and into two bottles
of Robertson's meat medium in order to detect anaerobic
infection. No contamination occurred in the pilot trial.
The cell suspension that was returned to the Cardio¬
thoracic Unit was mixed with 0.5 mis of standard intra¬
dermal BCG. Glaxo (8 - 26 x 10^ viable units per ml).
This cell suspension mixed with BCG. was then injected
in four different sites intradermally and subcutaneously
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into the anterior and lateral aspects of the thighs. This
injection of autograft was repeated two and ten weeks
after operation (Figure 3)«
Radiotherapy
At the time of operation a braided steel marker was
placed in the stump of the upper lobe bronchus. Three
weeks after operation, or occasionally a little later
depending on the patient's condition, a course of radio¬
therapy was given to the mediastinum in the region of the
hilum as indicated by the steel marker. The full course
of radiotherapy consisted of 3,5^0 rads tumour dose which
was given in l6 treatments over 22 days.
Immunological Tests
Immunological screening of the patient was performed
two weeks before operation, at 2, 7 and 12 weeks after
operation and at three monthly intervals thereafter over
the course of two years. During this time, none of the




0.1 ml of Tuberculin PPD., Weybridge (lO Old Tubercul
units) was injected intradermally into the volar surface
of the forearm. The maximum diameter of induration at
^-8 hours was recorded.
DNCB. Test
Different strengths of dinitrochlorobenzene (DNCB.)
were made up by dissolving DNCB. crystals in acetone. The
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DNCB. oil the skin inside a 2 cm diameter brass ring
which was fastened to the skin by micropore. The DNCB.
was dried onto the skin after evaporation. The patient
was instructed not to wash the arm for 48 hours.
Between 10 and 14 days later a strip of 5 patches
was applied to the volar surface of the other forearm
(Figure 4).
These patches were impregnated with DNCB. in the
following dilution: 62. 5> 125> 250, 500 and 1000 micro¬
grams per ml. The strip was fastened to the volar surface
of the forearm and removed 2 days later. The reaction was
graded from 1 to 4 according to the degree of erythema
and oedema produced at each site. A positive DNCB. reacti
analogous to a positive tuberculin test, was taken as
erythema covering the area of the disc treated with
500 micrograms per ml. (Figure 5)•
Laboratory Tests of Immunological Function
At each immunological screening, 35 mis of venous
blood was withdrawn. 5 mis were placed in a sequestrene
tube and sent to the haematology laboratory for estimation
of the total and differential white cell count from which
the total lymphocyte count was derived.
30 mis of blood was divided between 3 heparinised
tubes and transferred as quickly as possible to the
laboratory. At the same time similar blood samples were
taken from controls who were on the same hospital premises
at the same time. These controls were either healthy
members of staff over the age of 40 or other patients
Fig.4D.N.C.B.impregnatedpatch sns ripapplietofore rm
Fig.5StronglypositivereactionstD.N.C.Ba48hours.
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who were not suffering from malignant disease and who
were not taking immunosuppressive drugs.
Estimation of T and B cell counts
Twenty mis of heparinised whole blood was separated
on Ficoll-Triosil mixture to provide lymphocytes for the
estimation of T and B cells by the rosetting technique
and for the lymphocyte transformation studies (MacKie,
Sless, Cochran and de Sousa, 1976). For T lymphocyte
count, 0.25 ml aliquots of lymphocyte suspension were
incubated for 15 - 20 mins. at 37°C with an equal volume
of 1 °/o washed sheep red blood cells. The suspension was
centrifuged at a low speed with the formation of cell
pellets. These were incubated for 2k hours at ^-°C. The
cells were then gently re-suspended and the percentage of
rosette-forming cells was estimated. A rosette-forming
cell was defined as a lymphocyte whose surface was touched
by a minimum of 3 red blood cells. 200 cells were counted
in all.
For the estimation of B lymphocytes, 0.25 ml aliquots
of a 1 °/o suspension of sheep red blood cells which had
been freshly coated with 1/2000 rabbit anti-sheep red
blood cell haemolysin and normal human plasma as a source
of complement were centrifuged at low speed with an equal
volume of the lymphocyte suspension to form cell pellets.
These pellets were incubated together at 37°C for 15-20
minutes and then re-suspended. The number of rosette-
forming lymphocytes was then counted. The count by this
method will have included residual monocytes in the
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lymphocyte-rich, preparations but such contamination has
been shown to be < 5% of total cells recovered after
Ficoll-Triosil separation.
Lymphocyte Transformation Studies
0.5 x 10^ lymphocytes were incubated in culture medium
O /
in a moist 37 C chamber with 5°/° C0The culture medium
used was Eagle's medium buffered with 2% Hepes buffer
and enriched with 10% foetal calf serum. Phytohaemagglutinin
(PHA., Wellcome) was used at a final dilution of 1 in 10
and pokeweed mitogen (PWM.) (Grand Island Biological Company)
was used at a dilution of 1 in 5* The cultures were
lb
incubated for 72 hours. C-thymidine was added for the
last b hours (0.05 microcuries per tube). After extraction
of cell suspensions with 10% trichloracetic acid and 2 ml
absolute alcohol, the filter paper was dried in air for
> b hours. 5 ml* of liquid scintillator was then added.
The radio-activity was measured in a Packard tricarb
scintillation counter and expressed as counts per minute
per 10 cells. Transformation ratios were calculated as
lb
ratios of the uptake of C-thymidine after exposure to
the mitogen to uptake when no mitogen was added to the
culture medium.
Out-patient Follow-up
Patients were seen at the out-patient department for
the first time 10 weeks after operation and b weeks after
the course of radiotherapy. Thereafter they attended
at three monthly intervals until two years after operation
and at six monthly intervals up to five years after
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operation. At each, attendance, they were seen by Dr. I.
McHattie and the author. A history of relevant complaints
was taken and a physical examination to detect evidence
of tumour recurrence or metastases was performed. The
patient had a postero-anterior chest radiograph. Scans
of bone, brain or liver were carried out as indicated.
Finally a note was made about the patient's activity and
employment. This information was recorded on a standard
form (Figure 6).
Statistical Methods
Student's t test was used to determine significant
differences in all the immunological tests except for those
of lymphocyte transformation by mitogens and PPD.. In
the latter, a Wilcoxon 2 sample test was used, because of
the lack of normal distribution of the readings. Statistical
analysis was performed by Mr David J. Hole, Statistician,
The Cancer Surveillance Unit, Ruchill Hospital.
Histology and Staging
The histology of the tumour tissue removed at operation
was determined with reference to the WHO histological
classification of lung tumours. TNM. staging was performed
by a pathologist from a different hospital (Dr. W.G.S.
Spilg, Victoria Infirmary) who was unaware of the treatment
given and the subsequent progress of any of the patients.
The tumour of each patient was allocated to one of three
stages as indicated by the American Joint Committee for
Cancer Staging and End-results Reporting, (1979)*
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The basic clinical details of the 15 patients in the
Pilot Trial are given in Table 1. The age, sex and mean
measurements of body size were similar in the two groups.
All except one of the patients had been smoking cigarettes
up to the time of hospital admission. One patient had
given up smoking three years previously.
Pathology
Pathological details of the tumours are given in
Table 2. It can be seen that there was a higher proportion
of squamous cell carcinoma in the non-autograft group. In
two cases the co-existence of substantial areas of squamous
cell carcinoma and adenocarcinoma tissue led the pathologist
to include both histological diagnoses. There was a
higher proportion of Stage III carcinomas in the non-
autograft group.
Operation and Radiotherapy
A higher proportion of the autograft patients under¬
went lobectomy. Only five patients in each group completed
post-operative radiotherapy. The reasons for failure to
complete treatment were: early post-operative death (l),
patient refusal to continue with treatment (l), poor
general condition (l), and poor condition combined with




No. of females 1 2
No. of smokers 7 7
Mean Age 58 53
Mean Weight (kg) 72.5 66.3
Mean Height (cm) 17^ 169
Mean FEV,
1 -L • U
(% of predicted) 78 69
Table 1. Pilot Trial patients: initial clinical details.
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AUTOGRAFT NON-AUTOGRAFT
Histology Squamous cell carcinoma 2 5




Stage I 6 b
II 1 0
III 1 3
Operation R. side operation 3 3
Lobectomy 6 b
Pneumone c t omy 2 3
Radio¬
therapy Completed course 5 5
Total in each group 8 7
Table 2. Pathology, staging and treatment in Pilot Trial.
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Immunological Profile
In order to show that randomisation produced two
groups of patients with comparable immunological function
I have drawn up Table 3 which gives the mean pre-operative
results in the two groups. DNCB. testing was not carried
out pre-operatively in the pilot trial.
POST-OPERATIVE CLINICAL RESULTS
Clinical Measurements
A considerable degree of caution is necessary in
drawing conclusions from the clinical results of the pilot
trial because of the small numbers involved.
1. Survival Data
A survival curve is shown in Figure 7» Table k gives
the percentage of patients surviving at different interval
up to five years after operation. The overall results are
similar. Although the autograft group appear to have
fared worse in that only two out of eight patients survive
at the end of five years, two of the six deaths in this
group were due to causes other than tumour recurrence
whereas in the control group three of the four deaths were
due to tumour recurrence. The number of deaths due
to tumour recurrence were thus k and 3 respectively in the
two groups.
2. Freedom from Tumour Recurrence
Figure 8 and Table 5 show the proportion of patients
in each group alive and free from clinical and radiograph!
evidence of tumour recurrence during the five years after
operation. It can be seen that there is no significant
difference between the two groups.
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AUTOGRAFT (8) NON-AUTOGRAFT (7)
Total wbc x 10^/l 8.9 10. 4
Total lymphocytes/
cu.mm. 2392 2731
fo T cells 47 40
T cell number/cu.mm. 1079 1254
% B cells 27 31
B cell number/cu.mm. 7^1 1005
PHA. ratio 185 115
Pokeweed ratio 52 4l
Tuberculin test (mm) 23 19
Table 3- Mean values of immunological measurements in
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3• The sites at which metastases first appear (Table 6).
There is no support for the view that systemic
immunotherapy reduces the incidence of distal metastases
relative to local recurrence.
4. Activity
In Table 7» an attempt has been made to assess the
quality of life of those patients who were alive one year
after operation. Again no difference was noted between
the two groups.
5• Unwanted effects
Five of the seven patients treated with intradermal
irradiated autologous cells and BCG. developed significant
fever during the first 48 hours after treatment. By the
end of 48 hours some induration and erythema at the site
of injection could be seen and this increased during the
next few weeks. By two months after operation, fluctuant
swellings were present at the injection site and during
the next two months these discharged cellular and fluid
debris with the formation of ulcers. In one case these
were between 10 and 25 cms in diameter (Figure 9)* The
ulcers persisted from six to nine months and then started
to heal. By one year healing with scar tissue formation
had taken place (Figure 10).
All five patients with severe local reactions had
tuberculin test results in excess of 20 mm. In contrast
the two patients with relatively mild reactions had initial
tuberculin tests at or below this value.
No patients developed clinical or biochemical evidence
6b
Site of tumour





Table 6. Site of initial tumour recurrence in the pilot
trial patients.
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Grade of Activity Autograft (5) Non-autograft (4)
Full activity 3 3
Limited activity 2 1
In hospital 0 0
Table 7« Level of activity one year after operation
in the pilot trial.
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Fig. 9 Ulcers on anterior surface of
thigh of pilot trial patient six
months after injection of B.C.G.
and autologous tumour cells.
Fig. 10 Healed lesions on anterior surface of thigh of pilot trial
patient one year after injection of B . C. G . and autologous
tumour cells.
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of liver function impairment and in the two patients who
died from tumour recurrence and had autopsies, granulom¬
atous hepatitis was not reported.
Ten patients completed post-operative radiotherapy
and seven of these had lobectomy. A striking feature
was the degree of fibrosis and shrinkage which occurred
in the remaining lobe on the operated side during the
following year. Figure 11 shows the chest radiograph
taken one year after left lower lobectomy in one patient
from the autograft group who had a full course of radio¬
therapy. In contrast Figure 12 shows a chest radiograph
taken one year after right lower lobectomy in a patient
from the main trial who did not receive post-operative
radiotherapy. The pilot trial patient and one other patient
from the same group subsequently developed infection with
Aspergillus fumigatus involving the fibrotic lung.
Post-operative immunological results
It should be appreciated that early in this study,
laboratory measurements were not achieved on all the
specimens submitted for immunological tests. The reason
for this included the clotting of cells, especially where
the cell count was high, insufficient numbers of cells
in the specimen, or failure of cells to resuspend after
centrifugation. This fact, coupled with the death of
three patients during the first six months meant that the
number of results recorded at any one time more than three
months after operation was insufficient for analysis.
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Fig.11. Chest radiograph taken one year after left
lower lobectomy in a pilot trial patient who
had a full course of radiotherapy. It shows
extensive opacification and shrinkage of the
remaining lobe of left lung.
70
Fig. 12. Chest radiograph taken one year after right
lower lobectomy in a main trial patient who
did not receive radiotherapy.
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Laboratory Measurements
A major problem with laboratory measurement of
immunological function is the wide variation in results
recorded in the same patient over a period of time.
Hence in the pilot trial, where the number of patients
was small, changes in the mean value, which appeared
striking when displayed graphically, were not always
significant when analysed statistically. In all the
figures shown, the post-operative results are given as
a change from the mean pre-operative results and significant
differences (p < 0.05) are indicated by an asterisk. These
results can be summarised as follows:
1. Total leucocyte count (Figure 13)
A rise two weeks after operation followed by a
fall during the period following radiotherapy in the
autograft group but no change in the non-autograft
group.
2. Total lymphocytes
A fall in total lymphocyte count, significant
only in the autograft group (Figure 14) after
radiotherapy.
3. T lymphocytes (percentage, Figure 15, and absolute
numbers, Figure l6). A rise in the autograft group
at seven weeks followed by a significant fall in
both groups presumably resulting from radiotherapy.
There was no significant change in the percentage
and absolute numbers of B cells, or in reactivity to
PHA. or PWM.
Fig.13Meanchangeintotalw.b c.countduri gpostoperativeeriodi il ttri l.
WEEKSAFTEROPERATION
2712
Fig.14Meanchangeintot llymphocytesafteropera ionilotriatie t .
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Fig. 15 Mean change in percentage T cells after operation
in pilot trial patients.
Fig.16
Meanch ngeinabsolutenumbersofTcellft roperationi pilottrialpatien s.
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Tuberculin Test
Tuberculin reactivity increased at two weeks in the
autograft group and subsequently decreased in both groups
after radiotherapy (Figure 17)* DNCB. reactivity was
only tested post-operatively in the pilot trial. It
increased equally in both groups on the second challenge,
a finding which was repeated in the main trial.
MODIFICATION OF THE PILOT TRIAL PROTOCOL
Our preliminary results suggested that this form of
specific immunotherapy had produced changes in immuno¬
logical function which might be beneficial to the patient.
Unfortunately two elements in the treatment protocol were
together producing unacceptable discomfort to the patients.
The lesions on the legs were painful and made walking
difficult. This discomfort was becoming marked at the
time at which the patients underwent their course of radio¬
therapy. This involved transport by ambulance or taxi
to another hospital some 15 miles away. The combined
effects of the leg lesions and the daily travel caused
the withdrawal of three patients from radiotherapy and
it was followed by a strong plea from our surgical
colleagues for a change in the protocol.
By that time other workers had been using a multiple
puncture method of administering BCG. percutaneously and
this had produced considerably less local reaction than
that which our patients had experienced (Home, 1976;
Pines, 1976). Because the local reaction was most severe
in patients with a strong tuberculin reactivity, it seemed
Fig.17
Meanchangeinmaximumdia eterofindur tion48h s. tuberculinr actioafteroperationinpiloti ltients.
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likely that intradermal BCG. rather than the.injection of
cells was mainly responsible for the ulceration. We
therefore decided to administer BCG. by this percutaneous
technique using a 20 needle Heaf gun. Moreover, because
the thighs were thought to be more prone to infection,
the deltoid region of the upper limbs was chosen for the
BCG. injection.
Radiotherapy had been given because of the belief
that an important role of immunotherapy was to render the
tumour more sensitive to radiotherapy. This belief was
based on the effect of irradiated autologous tumour cells
in increasing the effectiveness of radiotherapy in delaying
the rate of growth of benzypyrene—induced sarcomas in
rats (Haddow and Alexander, 1964). However previous
investigations of post-operative radiotherapy in patients
undergoing resection of bronchial carcinoma had not shown
striking improvement (Paterson and Russell, 1962).
For this reason it was decided that radiotherapy would
be omitted from the protocol in the future.
By that time, Powles et al.(1973) had been injecting
allogeneic irradiated tumour cells into limbs treated
previously with percutaneous BCG. This technique led
to the idea that BCG. might be used to "prepare" the
lymph nodes adjacent to the site of injection for a
response to injection of autologous irradiated cells.
Because it was felt that the first injection of these
cells should be given immediately after operation when
the cells were fresh, it was necessary to give one
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percutaneous treatment with BCG. to all patients before
operation. The "Main Trial" can therefore be considered
as a comparison of strong repeated post-operative specific







The scheme of the main trial, entered by the first
patient on August 23rd, 1976 and the last patient on
August 23rd, 1979 is given in Figure 18. The procedure
was generally similar to that of the pilot trial and the
changes can be considered under the following headings:
Immunological tests.
Immunotherapy regime.




Ten to lb days before operation for suspected bronchial
carcinoma, a tuberculin test and laboratory tests of
immunological function were performed. At the same time,
a sensitising dose of 2°/o DNCB. was applied to the forearm.
Between 2 and b days before operation these tests were
repeated and, in addition, challenge strips containing
weak dilutions of DNCB. were applied to the other forearm.
These were read k8 hours later, just before operation.
The tuberculin and laboratory tests were repeated at 1,
2, 3 and 7 weeks and the DNCB. at 3 and 7 weeks after
operation.
(b) Laboratory methods
Lymphocyte transformation by PPD.
The same laboratory tests were used as those in the









































was measured. 100,000 units/ml. PPD.were dialysed against
distilled water to remove phenol (preservative) and
sterilised by millipore filtration to remove contaminants.
This was diluted so that 50 pi. added to 1 ml. of culture
medium gave concentrations of 100 units/ml. to which the
lymphocytes were exposed. Transformation ratios were
14
calculated as ratios of uptake of C-thymidine after
exposure to PPD. to the uptake when no mitogen was added,
as for the mitogen-induced lymphocyte transformation tests
described in the pilot trial.
Immunotherapy regime
(a) Routine
Patients who were believed to have resectable lung
cancer received percutaneous BOG. by 20-needle Heaf gun
into the deltoid region of one arm approximately one week
before operation. Randomisation and, in those allocated
to the autograft group, preparation of the cell suspension
were carried out as in the pilot trial.
On the day of operation, patients in the autograft
group were injected intradermally and subcutaneously with
3 ml. of tumour cell suspension. The injection site was
the deltoid region of the arm. The range of cell counts
was 0.3 to 68.0 x 10^/ml. and the mean cell count was
25.1 x 106/ml. At the same time percutaneous BCG. was
injected into the deltoid region of the other arm. During
the next 3 weeks the autograft patients received serial
injections of tumour cells and percutaneous BCG. into the
deltoid regions of both arms so that the cells were injected
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into an arm "primed" with. BCG. the previous week,
(b) Percutaneous BCG. vaccination
0.3 ml. sterile water was added to freeze-dried
powdered BCG. Glaxo and the mixture agitated until
complete mixing had taken place with the production of
a suspension containing 50 to 250 x 10" viable organisms
per ml. This was drawn up into a syringe and dropped
over the injection sites. A heat-sterilised 20-needle
Heaf gun was adjusted to give an injection depth of 1 mm.
and applied to 5 sites in the region covered with BCG.
suspension. At each site, two sets of injections were
made, by rotating the gun through 90° for the second
injection. Thus 5 injection sites with 40 needle punctures
each were produced (Figure 19)«
Omission of Radiotherapy
No post-operative radiotherapy was given in the main
trial.
Follow-up Attendance
Patients were usually seen at the hospitals one
month after discharge, approximately 7 weeks after
operation, 12 weeks after operation and thereafter at 3
monthly intervals up to 2 years. After 2 years they were
seen at 6 monthly intervals. Follow-up of patients in
both trials continues at the present time. Tuberculin
tests were performed at each follow-up attendance during
the first 2 years after operation. The majority of these
and the second post-operative DNCB. test were read at 48
to hours in the patients' homes by the author but a
Fig.19Deltoidregionofafemalepatientinth iri l3w ksafterpercut n ous injectionofB.C.G.usi gamul iplep nc urH ag n.
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few attended Mearnskirk Hospital for reading of the
tests by Mr N. McSwan.
Measurement of DNCB. reactivity
In order to obtain a measure of DNCB reactivity, dose
response curves were constructed for each patient according
to their reaction to increasing strengths of DNCB. . The
DNCB. index was read off from the curve as the strength
of reaction (between 0 and at a concentration of 250 pg/ml.
Until September 30th, 1979> laboratory tests of
immunological function were performed at each attendance
during the first 2 years after operation. With the
cessation of the Cancer Research Campaign grant, these
tests were no longer available. Hence in patients entering
the main trial in 1978 and 1979* some of the postoperative
laboratory immunological data are incomplete although all
these patients had regular skin tests.
Extension to the Western Infirmary
In the main trial, 11 patients operated on by Mr
M.A. Turner at the Western Infirmary were recruited.
Comparison of autograft and non-autograft groups
Clinical, surgical, pathological and immunological
data from both groups of patient are shown in Table 8.
There is an excess of lobectomies among the control group
and of large cell carcinomas among the autograft group,
both of which might be expected to operate to the dis¬
advantage of the autograft group. Reference will be made
to the different proportions of T^N^ patients among






































Stage at 2 1 1
3 15 12
Mean tuberculin reaction (mm) 15. 8 17.9
Mean DNCB. reactivity (units) 1.4 1.2
Table 8. Characteristics of operable bronchial carcinoma
patients in main trial.
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CHAPTER 6
IMMUNOLOGICAL MEASUREMENTS BEFORE OPERATION
89
RESULTS
Combined pilot and main trial
No significant difference was found in the counts
of total white blood cells (wbc) and total lymphocytes
and in the percentages of T and B cells between patients
and controls (Table 9)* The percentages of B cells
measured were rather higher than would be expected with
the methods in use today but this did not affect the
comparison of the two groups. From Figure 20 it can be
seen that, whereas lymphocyte reactivity to PHA. and PWM.
were similar in patients and controls, lymphocyte reactivity
to PPD. was significantly depressed in the lung cancer
patients (p < O.OOl). In Figure 21 it can be seen that
the percentage of patients and controls with a positive
tuberculin test was similar but that a much smaller
proportion of patients compared with controls became
sensitised to DNCB.. This latter test was performed
before operation only in patients from the main trial.
MAIN TRIAL RESULTS
Immunological measurements before operation in relation
to the tumour and the clinical outcome
In Table 10, the preoperative immunological tests in
patients with stage 1 and stage 3 tumours are compared
for the main trial. Total lymphocytes (p = 0.08), total
B cells (p = 0.06) and the percentage of DNCB. positive
patients (p = 0.06) were appreciably lower in patients
with more advanced tumours. Tuberculin reactivity was
greater in patients with large cell anaplastic carcinoma and
adenocarcinoma than in squamous cell carcinoma (p < 0.05)
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Patients Controls
Total w.b.c. 9216 8535 per cu.mm.
Total lymphocytes 2663 2480 per cu.mm.
Percentage T cells 46 48 %
Percentage B cells 31 27 °/o
Table 9« Mean counts of total leukocytes and lymphocytes
with mean T and B cell percentages in combined
pilot and main trial patients.
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Fig. 21 Percentage of lung cancer patients before operation





Total w.b.c. 92^3 8235 per cu.mm.
Total lymphocytes 2666 I898 per cu.mm.
Total T cells 1063 578 per cu.mm.
Percentage T cells 38 33 %
Total B cells 898 335 per cu.mm.









Tuberculin test 19.5 14. 0 mm.
Percentage
positive DNCB.
test kk 18 %
Table 10. Immunological results from combined pilot and
main trial patients showing reduced total
lymphocytes, B cells and DNCB. reactivity
in Stage 3 compared with Stage 1 patients.
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but otherwise there was 110 significant difference between
different histological types (Table 11).
In Table 12 the immunological results in patients
surviving more than 2 years after operation are compared
with those of patients who died within this period.
Patients surviving more than 2 years had a higher mean
total lymphocyte count (p = 0.02). Otherwise there was
no significant difference between the groups. When
patients surviving 2 years without tumour recurrence and
those who had no evidence of recurrence at the time of
death were compared with patients who developed tumour
recurrence within 2 years of the operation, the total
lymphocyte count (p = 0.08) and the incidence of DNCB.
sensitisation (p =: 0.05) were found to be reduced in the
tumour recurrence group (Table 13)•
Correlation of lymphocyte transformation test results
with these different pathological and clinical features
proved disappointing. This was undoubtedly due to the
wide variability of results within groups and within
patients over a period of time. Cell counts and delayed
hypersensitivity skin (DHS.) reactivity were more stable
and less variable. These measurements seemed more reliable
in assessing immunological status.
DISCUSSION
Peripheral blood cell counts
The finding of similar levels of total wbc., total
lymphocytes, and T and B cells in patients and controls
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Death from
lung cancer Alive at
< 2 years 2 years
Total w. b.c. 8529 8913 per cu.mm.
Total lymphocytes 2093 2698 per cu.mm.
Total T cells 770 1075 per cu.mm.
Percentage T cells 36 36 fo
Total B cells 721 559 per cu.mm.









Tuberculin test lb. 6 H 00 • mm.
Percentage positive
DNCB. test 23 39 . %
Table 12. Mean pre-operation values for immunological
tests and percentage positive DNCB. reactors
in main trial patients in relation to survival
during first 2 years after operation. Total
lymphocytes are significantly higher in those







at 2 years or
time of
death
Total ¥.b.c. 85^3 8938 per cu.mm.
Total lymphocytes 2186 2638 per cu.mm.
Total T cells 802 IO65 per cu.mm.
Percentage T cells 36 35 %
Total B cells 722 539 per cu.mm.








Tuberculin test 15 18 mm.
Percentage positive
DNCB. test 21 k3 °/o
Table 13• Mean pre-operation values for immunological tests
and percentage positive DNCB. reactors in main
trial patients in relation to recurrence of
lung cancer within 2 years of operation.
Total lymphocytes (p = 0.08) and DNCB. reactivity
(p = 0.06) higher in tumour free group.
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and Roberts, Donohoe, Hewitt and Evans (1977) for localised
lung cancer (Table 1^). In contrast, two groups cited
found depressed T cells even in these early cases and
depression of total and T cells has been found in unselected
series of patients. In general, both total lymphocytes
and T cells become depressed in more advanced cases. B
cell elevation has been reported in squamous cell carcinoma
with regional extension (Ritts et al, 1977) but in no
other series.
This considerable discrepancy in findings may well
be due to the use of different control groups. Evidence
of the effect of smoking on immunological function and
the decline of this with age suggests that it is prudent
to use controls matched for age, sex and smoking habits.
This was done for total leukocyte and total lymphocyte
counts only in this study and also by McEvoy, Cowled,
McKenzie et al. (1979) alone of the authors listed in
Table ±k. Some workers have used as controls patients
with non-malignant pulmonary disease. These will probably
include a high proportion of patients with chronic
bronchitis and emphsema who are cigarette smokers.
Why does lymphopenia occur in lung cancer? McMahon
and Thomson (1980) have shown an inverse relationship
between the lymphocyte/total wbc. ratio in peripheral
blood and plasma Cortisol in serial diurnal measurements.
This might suggest that increased endogenous Cortisol
production depresses lymphocyte formation. In keeping
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levels are most severely depressed in advanced cases
(Roberts et al., 1977) where plasma Cortisols are highest
(Lichter and Sirrett, 1975)*
Alternatively the relative depression of both total
and T lymphocytes seen in some series (Table l4) may simply
indicate redistribution of lymphocytes from peripheral
blood to other sites. These sites might be tumour tissue
itself where concentrations of lymphocytes have been
described (loachim et al., 1976). This would explain the
rapid return to normal of T cell levels following tumour
resection (Dellon, Potvin and Chretien, 1975)* Lymphocytes
might also be sequestered in liver, spleen and lymph nodes.
However the latter was not confirmed by Syrjanen (1979)
who found that lymphocyte follicles, small and medium-
sized lymphocytes were less numerous in lymph nodes
draining lung cancers than in those draining gastric ulcers.
Lymphocyte mitogen induced reactivity
Lymphocyte transformation on exposure to a variety of
stimulants in vitro is a commonly used non-specific test
of cell-mediated immunity. The mitogens used include
phytohaemagglutinin (PHA.), concanavalin A (Con A) and
pokeweed mitogen (P¥M.). These are known as polyclonal
activators because they do not act as antigen and do not
depend on prior sensitisation of the lymphocytes for
their action. PHA. and Con A are thought to act mainly
on T cells and PWM. on both T and B cells. PHA. has
been considered the most useful mitogen for in vitro
tests to distinguish between lymphocytes from lung cancer
101
patients and those from normal controls.
Lymphocyte transformation tests can also be performed
with bacterial antigens such as PPD.. In contrast to
non-specific mitogens, these act only on lymphocytes
that have been sensitised to the antigen.
Numerous reports of depressed lymphocyte transformation
tests in unselected series of lung cancer patients have
appeared during the past 13 years of which some examples
are given in Table 15* As with cell counts, more attention
should have been paid to selection of controls in view of
the decline of PHA. reactivity with age (Barnes et al.,
1975) and the depression of cell-mediated immunity by
smoking. However even where these factors were considered
(McEvoy et al., 1979) PHA. reactivity was relatively
depressed. It has been possible to extract data on
localised lung cancer from 2 papers. There was no signifi¬
cant depression of lymphocyte reactivity compared with
controls except for reactivity to PWM. in one report
(jansen et al., 1979a).
What is the cause of depressed lymphocyte transform¬
ation by PHA. in lung cancer? One factor may be decreased
numbers of effector T cells. However this cannot be the
only explanation since reduced lymphocyte transformation
by PHA. has been reported in patients where the mean T cell
count was normal (McEvoy et al., 1979)* Another factor
may be the presence of suppressor cells in the cell
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from lung cancer patients through Sephadex G10 columns
restored PHA. responsiveness presumably by removing
adherent suppressor cells (Jerrells,Dean, Richardson
et al., 1978a). Moreover recovery of PHA. responsiveness
was also observed when lymphoid cells from lung cancer
patients were cultured with prostaglandin synthesis
inhibitors (Thomas, Huchet, Grandjon and MathSf, 1978).
Suppressor cells are believed to act by production of
prostaglandins. Their role in depression of cell-mediated
immunity in cancer has recently been confirmed by Mavligit,
Raphael, Calvo and Wong (1980) who showed that indo-
methacin, a prostaglandin inhibitor, restored local graft
v. host reaction in cancer patients where this had
previously been depressed. The fact that suppressor cells
are more numerous and active in advanced cancer (Han and
Takita, 1978) would explain why depression of PHA. activity
was not seen in the operable cases in this series and
in the 2 reports of localised disease cited.
A second cause of depressed mitogen reactivity in
lung cancer may be intrinsic defects of the lymphocytes.
Smetana, Vlastiborova, Matejkova et al. (1976) have
found increased numbers of immature and stimulated
lymphocytes in peripheral blood from lung cancer patients.
It may be that these cannot respond normally to mitogens.
Even where the polyclonal mitogen reactivity is found to
be normal by conventional methods, lymphocyte function
may be shown to be abnormal by newer techniques. Brzyski,
Konchanin, Baustin and Ruckdescel (1979) divided the
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lymphocyte proliferative response into nuclear-related
3events including H-thymidine uptake and membrane-related
events which consisted of transformation and blastogenesis.
Using flow-cytometry, they found that, in patients with
3
normal H thymidine uptake on stimulation by PHA.,
lymphocyte transformation and blastogenesis were signifi¬
cantly reduced. Colchicine and cytochalasin C could mimic
the effect of lung cancer when added to lymphocytes from
normal donors. These drugs impaired the microtubule-
microfilament related surface modulating assembly of the
lymphocyte. This may be one of the mechanisms whereby
lymphocyte function is impaired in lung cancer.
In a similar vein, Whitcomb and Parker (1977) found
that, although PHA. reactivity in newly diagnosed lung
cancer patients was similar to that of controls, PHA-
stimulated protein synthesis by the lymphocytes was
significantly reduced. In vitro lymphocyte DNA synthesis
was normal and the discrepancy was not explained by
reduction in T cell numbers.
The finding of depressed lymphocyte transformation
by PPD. with normal transformation by PHA. and PWM. has
not been reported by other workers. As cutaneous tuberculin
reactivity was normal in these patients (see later) it
suggests that, whereas the sensitised lymphocytes recognised
the antigen normally and were able to initiate the
appropriate inflammatory response, their transformation
was inhibited by some other factor. Again suppressor
cells may be the culprits. BCG. in vivo increased
105
suppressor cell activity (jerrells et al. , 1979) so it
is possible that tuberculoprotein (PPD. of tuberculin)
enhances suppressor cell activity in vitro.
Rees, Rossio, Wilson et al. (1975) also found a
discrepancy between PHA. and PPD. reactivity but in the
opposite direction. In their study there was some
correlation between the tuberculin test and lymphocyte
stimulation by PPD.. Moreover PHA. and PPD. reactivity
were found to correlate well in a study of normal subjects
receiving BCG. vaccination reported by Thomas, Coy, Lewis
and Yuen (1971)•
Delayed hypersensitivity skin tests
In vivo testing of cell-mediated immunity in humans
with lung cancer has taken the form of testing skin reactivity
to recall or new antigens. Recall antigens are those to
which the subject is likely to have been exposed previously;
new antigens are those which have not been encountered












Keyhole limpet haemocyanin (KLH)
io6
In our study tuberculin was chosen because it was
readily available and because the author had experience of
its use in other studies. DNCB. had already been used
in one of the hospitals where these investigations were
taking place.
From Table 16, it can be seen that 2 of 3 studies
in the literature found no depression of tuberculin
reactivity in patients with localised lung cancer and
this was in agreement with the findings in this investigation
both for mean tuberculin reaction (Table 8) and for the
incidence of positive tuberculin tests (Figure 21). The
exception was the report of Israel et al. (1973) i-n which
the incidence of positive tuberculin tests in controls
was taken from a population survey. They used 3 units of
Pasteur PPD. which produced > 5 mm induration at 72 hours
in 80% of adult males in an urban population. No mention
of age-matching was made and it seems doubtful whether
such a high incidence of reactivity would be found in
controls who were matched for age and smoking habits. In
contrast we used 10 units of PPD. (Weybridge) which produced
a reaction of more than 10 mm at 48 hours in 68% of
controls matched for age, sex and smoking habit who were
also taken from a population survey in an urban area
(Hawthorne, personal communication).
Holmes and Golub (1976) found that virtually every
case with resectable lung cancer became sensitised after
one exposure to DNCB.. They did not use controls but,
of the 3 groups of workers who did, only one confirmed
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in localised lung cancer (jansen et al. 1979 )• This
discrepancy cannot be explained by the use of matched
controls as in general these tend to have a higher smoking
incidence and to be older than unselected healthy controls
drawn from hospital and laboratory staff, blood donors
and volunteers.
Vanebo et al♦ (1976) claimed decreased incidence of
DNCB. sensitisation in all stages of lung cancer. However,
although 20 out of 20 normal subjects became sensitised
to this antigen, as many as 29 out of 35 lung cancer
patients between stages 0 and 2 were also sensitised.
Failure of 6/35 to become sensitised can hardly be con¬
sidered to represent overall depression of sensitivity
to this antigen.
In vivo DNCB. reactivity in lung cancer correlated
well with in vitro lymphocyte transformation in mixed
lymphocyte culture (Holmes and Golub, 1976). Both tests
measure the ability to recognise foreign material (hapten
and allogeneic lymphocytes respectively) and the ability
to respond to these. In patients already possessing
lymphocytes sensitised to tuberculoprotein, the tuberculin
test measures only the ability to respond to antigen.
Decreased DNCB. reactivity coupled with normal tuberculin
reactivity is therefore taken to indicate impairment of
the afferent limb of the immunological response (Holmes
and Golub, 1976) (Figure 22).
Generalised depression of immunological tests has











Figure22.Delay dhypers nsitivitykinactiontotubercul ndDNCB.
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some earlier studies, no correlation was found between
DHS. tests and lymphocyte transformation tests (Golub,
O'Connell and Morton, 197^+5 Saumon, Dermenghem, Saint-
Paul et al., 1968). However in later studies, DHS tests
have correlated with laboratory tests of immunological
function (lymphocyte migration inhibition by allogeneic
Cl4 cell line antigen, Cerni and Mickshe, 1976; leukocyte
migration index, Pouillart et al., 1976). In our own
study the striking relationship was between DNCB. reactivity
and lymphocyte transformation by PPD.. As the former
tests the afferent and effector limbs of the immunological
response and the latter, only the effector limb, this ■
finding argues in favour of a more generalised depression
of immunological function.
DHS. tests using tumour extracts were first employed
by Stewart (1969). Positive reactions were found in k
out of 9 lung cancer patients.
Two mechanisms of depression of DHS. reactivity in
lung cancer have been postulated. The first is inhibition
by factors present in the serum (Golub et al., 197^)*
This was suggested by the close correlation of DNCB.
reactivity with the mixed lymphocyte culture transformation
test which was markedly inhibited by sera from lung cancer
patients. However if this were the only mechanism, DNCB.
and KLH. reactivity would be expected to disappear at the
same time as inhibitory migratory activity of serum rather
than before as found by Pouillart et al. (1976).
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A second mechanism is depression of cell-mediated
immunity by endogenous Cortisol. De Meester, Golomb,
Dudek et al♦ (1979) found an inverse relationship between
the degree of DHS. reactivity and the midnight serum
Cortisol as the disease progressed. The hypothesis was
tentatively formed that elevated serum Cortisol was
responsible for decreased skin and lymphocyte reactivity.
However in the discussion following this paper it was
pointed out that even the peak concentrations of Cortisol
encountered in these patients had no effect on mitogen-
induced lymphocyte transformation in vitro.
Immunological tests before operation and the stage of the
tumour
In general, cell-mediated immunity becomes depressed
with progression of lung cancer. This study has shown
that total lymphocytes, B cell count and DNCB. reactivity
were reduced in stage 3 cases compared to stage 1 cases.
Serial measurements of total lymphocytes in lung cancer
have shown a fall with progression (Anthony et al., 1975)
and Vanebo et al. (1976) showed that significantly more
patients with stage 3 disease had total and T lymphocyte
counts below the 10th percentile of control patients.
B cell depletion in advanced disease has not been reported.
However it is now recognised that the method used in our
study may have counted a substantial number of monocytes
and T cells.
DHS. reactivity to recall and new antigens has also
been depressed in stage 3 squamous cell carcinoma (Jansen
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et al., 1979a)• Ruszel et al. (1978) found positive
reactions to DNCB. in 51% of all lung cancer patients
but in only 33% of patients with advanced disease.
Similarly depressed lymphocyte transformation ratios
have been found in some series (e.g. Giuliano et al.,
1979) though not in our own cases. It is of interest
that, during the evolution of lung cancer, DHS reactivity
to DNCB. or KLH. disappeared before reactivity to recall
antigens (Pouillart et al. , 1976).
Immunological tests before operation and histology
In this study tuberculin reactivity was significantly
greater in patients with large cell anaplastic carcinoma
and adenocarcinoma than in those with squamous cell
carcinoma (Table 11). Jansen et al. (1979a) found greater
depression of DHS. and laboratory tests of cell-mediated
immunity in squamous cell carcinoma. In particular,
there was a greater incidence of negative tuberculin tests
in patients with squamous cell carcinoma stage 3 than in
patients with adenocarcinoma and small cell carcinoma.
Further indirect evidence of more pronounced suppression
by squamous cell carcinoma comes from Dellon et al. (1979)
who found that depression of total and T lymphocytes in
this tumour but not in adenocarcinoma indicated a bad
prognosis.
Most other comments on the immunological activity of
different histological types group adenocarcinoma and
squamous cell carcinoma together and contrast them with
anaplastic tumours including small cell carcinoma. For
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example Weese, Oldham, Herberman et al. (1976) found that
depression of T cell counts and lymphocyte transformation
tests was greater in patients with anaplastic tumours, a
finding confirmed for T cells by Huang, Yang and Rafla
(1978). Similarly Ioachim, Dorsett and Paluch (1976)
found increased plasma cells and lymphocytes in squamous
cell carcinoma compared with undifferentiated and small
cell carcinoma tissue. As small cell carcinoma patients
were deemed unsuitable for surgery and therefore excluded
from our series, I cannot comment on the relative
immunological behaviour of these from our own results.
Howevfer it seems that immunological depression may be even
more pronounced with these tumours than with squamous
cell carcinoma.
Immunological tests before operation and clinical progress
after operation
This investigation has shown that total lymphocyte
counts and DNCB. reactivity were the only tests which
correlated significantly with prognosis. The prognostic
value of total and T lymphocytes was described by Dellon
et al. (l979)» They found that all patients with tumours
other than adenocarcinoma who had total lymphocytes less
than lOOO/cu.mm. and T cells less than 750/cu.mm. died
within 3 months whereas 55% of those with higher levels
were surviving and free from clinical evidence of tumour
recurrence over nine months later. The prognostic
significance of total lymphocyte count was confirmed for
stage 3 tumours by Wanebo et al♦,(1976)and of T cell
counts by Anthony et al. (l975)»
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The prognostic value of the tuberculin test in
operable lung cancer was reported by Israel et al. (1973)*
Since then there have been numerous reports of the
relationship between DNCB. reactivity and prognosis.
Concannon, Dalbow, Davis et al♦ (1978a) built up a profile
of immunological tests in patients referred for radio¬
therapy and found that the DNCB. test was the best pre¬
dictor of survival. De Meester et al. (1979) found a
parallel fall in the percentage of patients with a positive
reaction and the current median survival. Liebler et al.
(1977) found that depress ion of DNCB. reactivity was
associated with decreased survival at all stages of the
disease. The only contrary report was that of Wanebo
et al. (1976) who found no significant difference in
survival between DNCB. positive and DNCB. negative patients
in each stage of the disease.
In our investigation, lymphocyte transformation
studies did not correlate with clinical results during 2
years after operation. This confirms the findings of
Braeman and Deeley (1973) for PHA. and PPD. In contrast,
Wanebo et al. (1976) found PHA-induced lymphocyte trans¬
formation a useful prognostic test in stage 3 carcinoma.
An extension of this observation was the discovery that
patients whose serum had a strong inhibitory action on PHA.
and Con A transformation of normal donor lymphocytes had
a poorer prognosis than patients whose serum had little
inhibitory effect (Giuliano et al., 1979 )•
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In general it can be said that, in an individual
patient, generalised depression of a battery of immuno¬
logical tests is likely to indicate a poor prognosis
but that the variability of results is such that any
single result taken alone is not of great prognostic value.
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CHAPTER 7
IMMUNOLOGICAL EFFECTS OF IMMUNOTHERAPY
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Results
In Table 17, it can be seen that there was no
substantial difference in mean readings of any of the
measurements made before operation between the autograft
and non-autograft groups. None of the differences
recorded reached significant levels and the overall base
line immunological function of both groups was thus
similar.
In Figures 23 to 27, changes in the various measure¬
ments from the pre—operative measurement were recorded
during the post-operative period. In both groups there
was a significant rise in total w.b.c. during the 3 weeks
after operation, and a rebound fall which reached signifi¬
cant levels (p < 0.05) only in the autograft group at 8,
lb and 17 months (Figure 23)• Total lymphocytes had
fallen significantly in both groups at 1 week after operation
and there were isolated falls at 8 months (non—autograft)
and 17 months (autograft) (Figure 2b). T cells followed
a similar pattern during the immediate post-operative
period although the mean fall in the control group was
not significant (p > 0.05) (Figure 25 ) •
As mentioned in the previous section, there was
extreme variation in the lymphocyte transformation readings
among and between individual patients. Thus although a
definite pattern of post-operative depression followed
by recovery of PHA-induced lymphocyte transformation was
seen in both groups (Figure 26) the change from the base






Total w.b.c. 8823 8600 per cu.mm.
Total lymphocytes 2397 2346 per cu.mm.
Total T cells 999 830 per cu.mm.
Percentage T cells 36 36 °fo
Total B cells 736 568 per cu.mm.








Tuberculin test 14 18 mm.
Percentage positive
DNCB. test 37 23 %
Table 17- Mean pre-operation values for immunological
tests and percentage positive DNCB. reactors
in the main trial autograft and non-autograft
patients. There are no significant differences
between the two groups.
*
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the statistical methods used. Similarly there were no
significant changes in lymphocyte transformation ratios
for PWM. and PPD.
As might be expected, much the most meaningful results
were obtained in the change from base line measurements
of the tuberculin test (Figure 27 ) « The mean values fell
during the immediate post-operative period though only the
fall in the non-autograft group was significant. A
subsequent rise in the autograft group was seen at 7 weeks
and at 5> 8, 11 and lb months. There was no significant
rise in tuberculin reactivity in the control group. The
mean DNCB. reactivity (Table 18) increased in both groups
at 3 and 7 weeks after operation.
Discussion
(a) Immediate post-operative results
One of the problems in assessing the value of immuno¬
therapy in lung cancer from published reports is that
workers have frequently claimed clinical success for their
treatment without producing any evidence of an immuno¬
logical effect (Djurovic and Decroix, 1978; Miyazawa,
Suemasu, Ogata et al., 1979; Hadziev, Kavaklieva-Dimitrova,
Mandulova et al., 1980). One reason for the omission of
these important data is an intention to publish the
immunological results elsewhere (e.g. Edwards and Whitwell,
197^)* Another is the misguided belief that, as the
immunological results do not appear to correlate with
other findings, they are better omitted altogether. A
third reason is that the shortage of time available at
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Patients Postoperative increased DNCB. reaction
3 weeks 7 weeks
Autograft 0-5 1.0
Non-autograft 0-5 1-7
Table 18. Skin reactivity to DNCB. at 3 and 7 weeks
after operation.
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scientific meetings means that clinical results are
included in preference to immunological findings in the
papers given and in their abstracts.
Another drawback in this field is the absence of
more specific tests. Ve know that killing of tumour cells
by macrophages and lymphocytes is an important part of the
host defence against tumours and that immunological stimul
act on these immunologically competent cells. Yet specifi
tests of macrophage activity and tumour cell killing are
time consuming and difficult to perform. In our own study
macrophage migration inhibition tests had to be abandoned
because of lack of laboratory time available. This is a
field where further progress is needed. Some attempts
have already been made including the demonstration of
increased lymphocyte cytotoxicity against tumour cells in
patients treated with BCG. - CWS., referred to by Yasumoto
Manabe, Yanagawa et al. (1979)• A more recent report of
a modified skin window technique to measure non-specific
macrophage chemotaxis also holds promise (Israel, Samak,
Bogucki and Samak, 1981).
In this investigation of immunotherapy before and
after surgery, it is right to bear in mind that the major
immunological event in the immediate peri-operative period
is thoracotomy and resection of the tumour under general
anaesthesia rather than the immunotherapy that was given.
Immunological effects of surgery have been under investig¬
ation for some years. Wingard, Lang and Humphrey (1967)
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found a fall in total w.b.c. and lymphocytes in rats
receiving intraperitoneal sheep red blood cells who were
given halothane. Lundy, Lovett, Hamilton and Conran (1978)
reported that in mice with methyl cholanthrene-induced
fibrosarcoma surgery and anaesthesia but not anaesthesia
alone impaired cell-mediated cytotoxicity and increased
pulmonary metastases. The effect of surgery, radiotherapy
and nutrition on immunological function has more recently
been reviewed by Ota, Copeland, Corriere and Dudrick (1979)*
In our study a rise in total w.b.c. was seen in both
groups during the first 3 weeks after operation. Cullen
and van Belle (1975) showed that this increase was
proportionate to the degree of trauma involved but did not
vary with different anaesthetic agents employed. Catecholamine
release was thought to be a major factor. In their study,
total lymphocytes increased slightly after operation.
However Slade, Simmons, Yunis and Greenberg (1975) showed
that in normal volunteer kidney donors, total, T and B
lymphocytes fell during operation. Return to normal values
occurred between 2 and 6 days after operation.
Several authors have found depressed lymphocyte
transformation by mitogens after surgery. This occurred
within a few hours of operation (Park, Brody, Wallace and
Blakemore, 1971) and returned to normal within a week.
There was slight variation in the extent and pattern of
response to different mitogens (Berenbaum, Fluck and
Hurst, 1973) but the prolonged fall in both groups seen
in our series was not described (Figure 26).
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Bancewicz, Gray and Lindop (1973) reported that all
9 of their tuberculin positive patients became tuberculin
negative after surgery and general anaesthesia and
remained so for 9-12 days. Endogenous Cortisol release
has been considered a possible factor in the depression
of lymphocyte reactivity to mitogens (Cullen and Van Belle,
1975)* However Berenbaum et al. (1973) showed that incubation
of peripheral blood leucocytes with Cortisol over 16 hours
did not reduce their response to PHA.. They also found
that reactivity to PHA. of lymphocytes from post-operative
patients was depressed even when their plasma Cortisols
had been normal. In our control group, this depression of
tuberculin reactivity was clearly seen whereas the
percutaneous BCG. given at the time of operation and twice
thereafter seemed to protect the autograft group from this
effect.
(b) Long term immunological results
The post-operative depression of lymphocyte transform¬
ation by PHA. and its subsequent recovery is illustrated
in Figure 26. Some reports of lymphocyte transformation
by mitogens in lung cancer patients treated with immuno¬
therapy are summarised in Table 19* It can be seen that
the results are rather variable. In the only other study
where specific immunotherapy was employed (Oldham, Weese,
Herberman et al., 1976) there was no change in reactivity
to any of 3 mitogens.
The discrepancy in lymphocyte transformation results







































Table19*Lymphocyteraitogen-inducedtransformationtes saft ri mu o h rapy;summ rfo e publishedreports.
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variable nature of the patients studied. Hence PHA
reactivity increased in lymphocytes from patients with
little or no tumour burden (Yasumoto et al., 1979; Gross
and Eddie-Quartey, 1976) but not in some patients with
locally advanced disease and/or metastases (Robinson,
Bartal, Cohen et al., 1977)* Contrary to our findings,
lymphocyte transformation by PPD increased in the 3 groups
tested who had received BCG.. Failure of this to occur in
our study may have been due to the short period of time
over which BCG. was given and to the fact that it was given
so soon after operation when immunological function was
depressed. Yet the expected increase in skin reactivity
to tuberculin did ensue.
Some reports of the effect of non-specific immunotherapy
on skin reactivity after resection of lung cancer are
summarised in Table 20. Levamisole is an immunorestorant.
As tuberculin reactivity is not generally depressed in
operable lung cancer, it is not surprising that this drug
did not increase reactivity to tuberculin. However in all
series where BCG. was given, there was increased mean
tuberculin reactivity, conversion of negative to positive
reactors or increased incidence of positive reactors during
the post-operative period. These measurements were made
within 3 months of operation and an exact time pattern was
not recorded. Our study showed that immunotherapy incorpor¬
ating percutaneous BCG. did produce increased skin reactivity
between 7 weeks and 11 months after operation. Thus the























Table20.Sompublishedreportsfthffectimm n t erapynskinreactivit PPD.andDNCB .
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advantage in freedom from tumour recurrence became less
clear cut.
Relatively few of the reports reviewed involved
specific immunotherapy. However Oldham et al. (1976)
reported an increase in reactivity to recall antigens in
patients receiving immunotherapy some of whom were given
allogeneic tumour cells and BCG.. Whether the addition
of tumour cells or extract to the BCG. increases the
tuberculin reactivity further is still unknown.
The finding of increased mean skin reactivity to DNCB.
in both groups on testing 3 and 7 weeks after operation
raises the question of whether repeated skin testing alone
increases skin reactivity to recall or new antigens.
Increased sensitivity to DNCB. has been reported on repeated
testing of patients treated with Levamisole and control
patients suffering from lung cancer of various stages by
Holmes and Golub (1976). However Krant et al. (1968)
found that 5/l6 DNCB. posit ive patients became negative
as the disease progressed to terminal stages.
Increased sensitivity to tuberculin on repeat testing
has been reported by Richards, Nelson, Batt et al. (1979)
in 6.6°/o of normal volunteers and by McKneally, Maver,
Kausel and Alley (1976a) in 5/12 tuberculin negative control
patients after successful resection of lung cancer.
However repeated testing on up to 9 occasions did not
produce an increase in the mean tuberculin reactivity of
the non-autograft group in the present study. Moreover
133 1
the tuberculin reactivity of the autograft group waned
gradually after 5 months following immunotherapy despite
continued tuberculin testing. At least in these patients
who had previously borne tumours, enhanced reactivity to
tuberculin did not occur with repeated testing.
13^
CHAPTER 8
CLINICAL RESULTS OF IMMUNOTHERAPY IN LUNG CANCER
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Results
By dividing up the post-operative period into intervals
of 3 months and recording the number of patients dying
or developing tumour recurrence during each interval, it
has been possible to construct actuarial life table curves
for survival and time free of tumour recurrence in all
patients and various subgroups (Figures 28 to 32). From
these it has been possible to calculate the percentage of
patients likely to survive or to be free of tumour recurrence
at annual intervals during the first 3 years after operation
and to derive the significance of differences between the
curves (Tables 21 and 22).
Except for those with stages 2 and 3 tumours, the
proportion of autograft group patients surviving and
remaining free of tumour recurrence at any one time during
the 3 years after operation was higher than that of the
non-autograft group. However with these relatively small
numbers of patients, the difference only approached
acceptable levels of significance in stage I patients
(Tables 21 and 22) and those who became sensitised to DNCB.
before operation (Tables 23 and 2b). In these groups only,
injection of irradiated autologous tumour cells and BCG.
may be effective.
From the graphs it is possible to detect a pattern
in which the curves diverge at 6 months. In patients
with stage I tumours, the difference becomes most marked
at 18 months, remaining substantial up to 3 years. However
when all patients are considered, the difference narrows
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% patients surviving
Fig. 28 Actuarially calculated survival graphs for all main
trial patients according to treatment group.
Difference not significant.
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% patients free from
tumour recurrence
Fig. 29 Actuarially calculated graph for time of tumour
recurrence of all main trial patients according to
treatment group . Difference not significant.
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% patients surviving
Fig. 30 Actuarially calculated survival graph of main trial
patients according to treatment group and stage.
For difference in stage I patients, p = 0.09.
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% patients free from
tumour recurrence
Fig. 31 Actuarially calculated graphs for time after operation
in which main trial patients remained free from tumour
recurrence, according to stage of tumour. For




















Fig. 32 Actuarially calculated survival graphs for main trial
patients according to treatment group and DNCB
reactivity before operation. Difference was significant,
(p = 0.02) for DNCB positive cases.
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1 2 3
Year Years Years Significance
autograft 69 51 45
All cases:
non-auto- N. S.
graft 55 39 32
autograft 76 72 67
Stage I:
non-auto- p = 0.09
graft 55 48 44
autograft 50 14 7
Stages II
and III: N. S.
non-auto-
graft 44 25 18
Table 21. Percentages of patients likely to survive at




Year Years Years Significance
autograft 56 46 46
All cases: N. S.
non-autograft 43 36 34
autograft 72 68 68
Stage I: p = o.09
non-autograft 52 44 44
autograft 29 7 7
Stages II
and III: N. S.
non-autograft 31 25 18
Table 22. Percentages of patients likely to remain free of
tumour recurrence at 1, 2 and 3 years after










autograft 92 77 69
p = 0.02
non-autograft 50 25 25
DNCB. negative:
autograft 59 36 32
N. S.
non-autograft 56 37 33
Table 23* Percentages of patients likely to survive at










autograft 77 69 69
p = 0.02
non-autograft 25 25 25
DNCB. negative:
autograft k5 32 32
N. S.
non-autograft 78 37 33
Table 27. Percentages of patients likely to remain free
of tumour recurrence at 1, 2 and 3 years after
operation according to pre-operation DNCB.
reactivity.
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at 21 months, partly because non-autograft patients with
stage 2 and 3 tumours did better than the autograft
group after 21 months.
Median times for survival and freedom from tumour
recurrence or progression have also been calculated for
all patients in both groups, for different stages and
histology (Tables 25 and 26). Here again the autograft
group fared better in general but the difference was only
significant at the p = 0.07 and p = 0.08 levels respectively
in patients with stage I tumours.
As it is now more than 2 years since entry of the
last patient into the trial, the number of patients actually
alive and free from clinical and radiographic evidence
of local or metastatic tumour 2 years after operation has
been recorded (Table 27)• Although the proportion was
higher in the autograft group, especially in stage I
patients, the differences were not significant.
The value of serial tests in detecting tumour recurrence
Because depression of DHS. tests and laboratory
measurements of cell-mediated immunity is more marked in
advanced lung cancer, it might be possible to detect
tumour recurrence after operation by serial measurements.
Indeed Shirakusa and colleagues (1978) showed that
circulating T cell levels fell with recurrence of tumour.
Figure 33 shows the individual measurements of lymphocyte
transformation ratios for PHA. in patients at the time of
tumour recurrence in relation to graphs of the mean change
in ratios for the 2 groups. Nine out of 17 patients had
146
Patients Autograft Group Non-autograft group Significanc
All 25 15 N. S.
Stage I >36 17 p = 0.07
Stages II
and III 9 9 N. S.
Squamous
cell >36 16 N. S.
Non-squamous
cell 25 15 N. S.
Table 25• Median survival times (months) calculated
for the first 36 months after operation.
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Patients Autograft Group Non-autograft group Signifleant
All 14 6 N. S.
Stage I >36 14 b II O • O 00
Stages II
and III 6 5 N. S.
Squamous
cell >36 10 N. S.
Non-squamous
cell 13 5 N. S.
Table 26. Median time free from tumour recurrence (months)
calculated for first 36 months after operation.
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No. °fo
All cases 18/40 45
Autograft
17/24Stage I cases 71
All cases 16/43 37
Non-autograft
Stage I cases 13/30 43
Table 27• Percentage of the patients in the autograft
and non-autograft groups who were alive and
free from clinical and radiographic evidence
of tumour recurrence 2 years after operation.
Differences not significant.
Changei
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values below the group mean at the time of recurrence
and only one had a value above. Similar patterns were
obtained for lymphocyte transformation ratios for PPD.
and for total w.b.c., but not for circulating levels of
total lymphocytes, T and B cells. Significant depression
of one or more measurements of immunological function was
common at the time of tumour recurrence but the pattern
was too variable for serial measurements to be of clinical
value.
Autopsies
Autopsies were performed in only 7 patients. This
low autopsy rate was due to the wide catchment area
served by the two participating hospitals. Thus many
patients died at home or in their local hospitals. As the
cause of death was usually seen to be recurrence of lung
cancer, local physicians and surgeons did not press for
autopsy examination.
Autopsy examination of h patients who received auto¬
logous irradiated tumour cells and BCG. did not reveal
any evidence of local tumour growth at the site of injection.
In none of these cases was there any evidence of granulo¬
matous hepatitis, a recognised complication of BCG. therapy.
Discussion
In an earlier section (Chapter 3)> I have described
some of the research work that was published before this
project started in 1975 and which influenced the design
of the project. Since this investigation started, numerous
other studies of immunotherapy in lung cancer have been
undertaken. Progress in some of these has been reported
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at regular intervals in published papers or abstracts
of scientific meetings. Thus the volume of literature
on the subject is now substantial. The methods of immuno¬
therapy used are summarised in Figure 2. (p«39)
Non-specific immunotherapy
(1) Systemic
The majority of immunological stimulants have been
avirulent bacteria and fungi or extracts of these. A few
have been relatively unknown before and, though claims
for benefit have been made, their value is unproven.
Examples of these include schizophyllan, a polysaccharide
prepared from a mushroom-like fungus (Oshima, Izumi, Kado,
Sato and Honda, 1980), bestatin, derived from Streptomyces
olivoreticuli (Svanberg, Widell and Cronberg, 1980) and
O.K. 432, prepared by incubating haemolytic streptococci
with potassium penicillin (Watanabe, Iwa and Yamamoto,
1980). Most studies of non-specific immunotherapy have
involved mycobacterial antigens, corynebacteria or immuno-
restorants such as levamisole and thymosin.
Occasional reports of the use of these in advanced
lung cancer still appear. For example Pines (1980)
combined repeated percutaneous BCG. with regular oral
levamisole in patients with locally inoperable squamous
cell carcinoma who had received radiotherapy. In patients
receiving levamisole and BCG. twice weekly there was
improved survival during the first 2 years only.
Early experience suggested that immunotherapy was
likely to be effective only where the tumour cell population
had been reduced to a minimum by surgery, radiotherapy
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or chemotherapy (Ritts, 1979)* Most interest has thus
centred round its use in surgical cases. Table 28 summarises
some of the better known trials of systemic non-specific
immunotherapy. In the majority of these, increased
survival compared with controls has been observed. Two
exceptions were British studies in whom a relatively low
dose of BCG. was given over a short period of time (Edwards
and Whitwell, 1978; Millar, Roscoe, Pearce et al., 198l).
(2) Local
Considerable interest was aroused by the early report
of a highly significant difference in the incidence of
tumour recurrence between patients receiving one post¬
operative injection of intrapleural BCG. and controls
(McKneally, Maver and Kausel, 1976). Significant differences
in freedom from tumour recurrence (p = 0.03) and survival
(p = 0.0k) were still being reported k years later
(McKneally, Maver, Bennett and Ruckdeschel, 1980).
However these results have not been confirmed in the
United Kingdom (Lowe, lies, Shore et al., I98O, Table 29)
or in a large multicentre trial in North America which
has yet to be published. It has been suggested that isoniazid,
given to controls as well as to the BCG. cases in the
original study, might have increased the incidence of
tumour recurrence in this "unprotected" group. However
this theory was refuted by the finding that the controls
had a similar survival curve to that of other surgical
cases not included in the study (McKneally, Maver, Alley

























































2yearsurvivalofst geIBCGcas s=92%, controls=60%,p<.01
Loweetal., 1980
IntrapleuralBCG.Glaxo
2yearsurvivalofst geIBCG.c s s=59%> controls=66%,N.S.
LudwigunCancer StudyGroup,I98O
IntrapleuralC.parvum
Nodifferenceb tweenBCG.groupandco trols, meanfollow-up60weeks.
Holmes,I98I
IntralesionalBCG.
Diseasefr esurvivalo rmedianfollow-upf 14months:BCG.group=55%>controls=37 •
Or
Table29*Resultsoflocalnon-specificimmunotherapyi a entsw oh veundergone resectionoflungcancer.
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investigation by the Ludwig Lung Cancer Study Group (1980)
but the early results have not been promising. However
this treatment has been shown to be beneficial in patients
with malignant pleural effusions (Millar, Hunter and
Home , I98O ) .
As some of the most impressive observations of the
effect of BCG. have been made after intralesional injection
of superficial tumours in animals and man, a group from
U.C.L.A. have experimented with injection of BCG. into
lung tumours (Holmes, Ramming, Mink et al., 1977)* This
injection has been achieved by percutaneous insertion of
a needle into the tumour on one occasion three weeks
before thoracotomy in patients with operable lung cancer.
Early follow-up results are promising (Holmes, 1981).
In tuberculin negative patients, this treatment produced
a typical granulomatous inflammatory reaction in the
tumour. This reaction was identical to that seen in animal
models and associated with systemic anti-tumour immunity.
Tuberculin positive patients had a different histological
reaction; there was widespread fibrinoid necrosis with
an inflammatory reaction consisting of more plasma cells
and the occasional formation of germinal centres within
the tumour. Of particular interest was the finding that,
while lymphocytes of tumours from untreated patients were
non-cytotoxic, BCG.-injected tumours contained lymphocytes
which were cytotoxic to tumour cells in vitro. Trans-
bronchoscopic intralesional injection of BCG. (Glaxo)
has also produced significant clinical and radiographic
improvement (Millar, Hunter, Wightman and Horne, 1980).
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Combination of non-specific Immunotherapy with chemotherapy
Many workers, especially Japanese, have sacrificed
the chance of assessing the role of immunotherapy alone by
using it only as an additive in patients who are also
being treated with a complicated chemotherapeutic regime.
For example, Watanabe et al. (1980) compared treatment
with O.K. 432 plus chemotherapy with chemotherapy alone in
160 patients undergoing surgical resection. Of those having
a curative resection, Gh°fo in the immunotherapy group and
52% in the chemotherapy group survived 5 years. This was
considered to be a significant difference. In this context,
immunotherapy may simply restore cell-mediated immunity
depressed by chemotherapy rather than act as an anti-cancer
agent in its own right. This reservation also applies to
patients in whom immunotherapy is combined with radiotherapy.
Van Houtte, Rocmans, Bondue et al. (1979) using levamisole
and Kerman and Stefani (1978) using BCG. achieved better
clinical results in patients receiving radiotherapy and
immunotherapy than in those receiving radiotherapy only.
Specific immunotherapy
Three trials of specific immunotherapy in lung cancer
are summarised in Table 30. In each of these, allogeneic
tumour cells with a mycobacterial adjuvant were employed.
In each study, the treated group fared better than controls
although the difference was significant only at the
p = 0.06 level in the N.C.I, study (Perlin, Oldham, Weese
et al., 1980). Clinical results in our own study are
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show an advantage for the autograft group when actuarially
calculated curves based on survival data during a follow-
up period of between two and five years are used. However
the difference in survival is significant only
in patients with stage I tumours and in those with positive
reactions to DNCB. before operation. When freedom from
disease recurrence was measured in the same way, a
significant difference between autograft and non-autograft
patients was seen only in stage I and DNCB. positive cases
(Tables 22 and 2k). The percentages remaining alive and
free from tumour recurrence at 2 years are given in
Table 27• Although the autograft group have fared better
in both respects, the difference was not significant.
Here are some possible reasons why patients in the
autograft group fared better than non-autograft patients:
1. Faulty randomisation
Randomisation was carried out by a lay clerical
assistant who did not know the patients or details of
their medical condition so that "selection" of envelopes
could not have taken place. However the randomisation
cards were stratified only for age and sex and not for
stage, histology or immunological reactivity. As can be
seen from Table 8, the two groups were equally matched
except for a relative excess of large cell anaplastic
tumours, stage I patients and pneumonectomies in the
autograft group. All these factors might be expected to
introduce bias against the autograft group. It can be
seen that DNCB. reactivity before operation was similar
in the two groups.
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2. Imbalance in number of cases with grading within
stage I
Shields (1980) drew attention to the importance of
TNM classification within stages in the prognosis of
surgical lung cancer patients. Tumours are classified as
if they are 3 cm. or less in diameter, surrounded by
lung or visceral pleura and without evidence of invasion
proximal to a lobar bronchus at bronchoscopy (American
Joint Committee for Cancer Staging and End-results
Reporting, 1979)* applies to tumours that are more
than 3 cm. in diameter, invade visceral pleura or cause
atelectasis or pneumonia extending to the hilar region
but that are at least 2 cm. distal to the carina at
bronchoscopy. tumours are those of any size which are
more proximal than 2 cm. from the main carina and which
invade adjoining structures. Nodal involvement is
classified into (no lymph node metastases),
(metastases in peribronchial and/or ipsilateral hilar
lymph nodes) and N^ (metastases in mediastinal lymph
nodes). Tumours confined to the chest that are T^N^,
TfNi and T^N^ are classified as Stage I and those that
are as Stage 2. Stage 3 includes any tumour confined
to the chest that is T^ and/or as well as those with
distal metastases (M^) Shields held that tumours
would be better placed in stage 2 rather than stage I
in view of their much worse prognosis than and
tumours. Among our patients, only one non-autograft
patient had a tumour but there was a larger proportion
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of tumours in the autograft Stage I tumours (13/24)
compared with the non-autograft stage I tumours (9/30)*
Although Shields (1980) found a difference in survival
between patients with TV N_. tumours and patients with T^N_10 2 0
tumours, patients with tumours in our series fared
rather worse than the whole group of stage I patients
(Table 31).
3• Tumour enhancement by preoperative BCG. in non-autograft
group
In a previous review, Bast, Zbar, Borsos and Rapp
(1974) described criteria necessary for successful BCG.
immunotherapy of tumours. One requirement was that there
should be an adequate number of organisms injected relative
to the number of tumour cells. It has been suggested
that inadequate numbers of BCG. organisms could lead to
tumour enhancement. It is thus important to consider
whether the single preoperative vaccination with BCG.
could have worsened the prognosis of the non-autograft
group. This can be done by comparing the clinical results
for this group with those taken from other surgical series
(Table 32).
It can be seen that the 2 year survival results for
all the non-autograft patients and for those with stage I
tumours are similar to the previous results from Glasgow
(Reid, Stevenson, Welsh and Barclay, 1961) and Edinburgh
(Le Roux, 1968) though worse than those reported from
two centres in U.S.A. Reid et al. (1961) blamed their
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T N
10
8 62 1 11
Table 31. Patients with stage I and the subgroup
tumours who were alive and free from tumour
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and emphysema which is so prevalent in Scotland. An
additional factor is undoubtedly the high prevalence of
coronary artery disease. b of our 83 patients died from
myocardial infarction more than one year after recovery
from their operation.
b. Effect of specific immunotherapy
The fourth reason for the difference may be that
autografts of irradiated cells with adjuvant BCG. do
increase the rejection of residual tumour cells by the
defence mechanism. Some support for this view comes from
the finding that patients capable of mounting a cell-
mediated reaction to a foreign hapten DNCB. seem most
able to benefit from the specific immunotherapy given.
A second point is that the time at which the clinical
effect is most obvious (l2 months) comes towards the end
of the period when tuberculin reactivity of the autograft
group is significantly raised above base line. The results
show clearly that the beneficial effect is only temporary
and this has clear implications for the design of future
trials.
It has been suggested that, if percutaneous or intra¬
dermal immunotherapy increases survival, it may do so by
stimulating the rejection of tumour cells which have been
deposited in distant organs. Robinson et al. (1977)
found that administration of methanol extraction residue
(MER.) of BCG. to lung cancer patients having radiotherapy
and/or chemotherapy reduced the incidence of visceral
metastases. A sign of effective immunotherapy might
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therefore be a relative fall in the incidence of distal
metastases compared to that of local recurrence. However
in our study, the pattern of recurrence was similar in
both the autograft and non-autograft group (Table 33)•
Unwanted effects
(a) Local
Moderately severe local ulceration can occur when BCG.
and related mycobacterial antigens are injected into the
skin. Perlin et al. (1980) had to reduce the number and
frequency of Heaf gun BCG. punctures in kj°/o of their
cases. Particularly severe local reactions occurred in
the autograft group of the pilot trial of this study when
BCG. was injected intradermally (Figure 9)* These occurred
especially in strong tuberculin reactors. Such reactions
are more severe when BCG. is given on the same day as
levamisole (Pines, 1980).
Local reactions also occur when BCG. is given intra-
pleurally in postoperative patients (Law, Spiro, Geddes
and Hodson, 1981). Eleven out of 39 of their cases
developed these; empyema in 6 and severe wound infection
in 5- Similar complications were reported by McKneally
et al. (1976a). Though previously reported after intra¬
dermal injection of melanoma cells, local tumour growth




Autograft group 7 8
Non-autograft group 10 10
Table 33- Pattern of tumour recurrence showing similar
distribution in both groups.
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(b) Systemic
Non-specific febrile reactions have occurred between
12 and ^-8 hours after cutaneous application of BCG. in
about half of the patients so treated. Transient elevation
of serum transaminases has occurred after intrapleural
BCG. (McKneally et al., 1976a) and C. parvum (Fox, Woods,
Tattersall and Basten, 1980). Severe hypotension occurred
in one of the patients treated with C. parvum. On the
whole lung cancer patients have tolerated immunotherapy
well and even intralesional BCG. has not so far produced
disseminated BCG. infection.
(c) Tumour enhancement
A clear warning that immunotherapy can enhance tumour
growth has come from numerous animal experiments (e.g.
Colmerauer, Koziol and Pilch, 1980). Possible examples
of enhancement of lung cancer have come from Nilsson and
Afeldt (1975) and McCracken, Heilbrun, White et al. (1980).
Defects of immunotherapy trials
It may surprise scientists working in other fields
that even now, 16 years after the start of modern studies
of immunotherapy in lung cancer, the value of immunological
treatment is not yet known. While it is clear that immuno¬
therapy is a relatively weak anticancer agent, another
factor is undoubtedly the poor design of many trials.
The single most important flaw in many of these is
the failure to use comparable controls. In a trial of
cancer therapy, the controls must be randomly selected
and prospective. Yet historical controls were used in
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several important trials including those of Yasumoto
et al. (1979) and Hadziev et al. (1980). Even in the
study of Jansen, The and Orie (1980) of BCG. immunotherapy
in 5^ patients with locally advanced squamous cell
carcinoma, no controls were added after the first 20
patients in each group had accrued. Moreover patients
who refused intrapleural BCG. were included in the
alternative systemic immunotherapy arm. It is well known
that patients may refuse treatment because their condition
is better or worse than more compliant patients. Such
selection may prejudice the results of survival studies.
Some workers have reported on the same immunotherapy
regime given to a heterogeneous collection of patients in
such a way as to make it impossible to separate the
effect of immunotherapy from that of the natural course
of the illness. For example Yasumoto et al. (1979)
administered BCG. cell-wall skeleton (CWS.) to five groups
of patients each differing from each other in the site
and extent of the tumour.
Another fault is to use too many treatment arms (e.g.
McCracken et al., 1980). The result is that each arm
contains only a few patients which makes it difficult to
draw valid conclusions about differences when they arise.
Frequently combined with this defect is the combination
of one or more forms of immunotherapy with chemotherapy
and/or radiotherapy. If it is possible to detect a
significant difference between the treatment arms, one
cannot be certain whether it is the immunotherapy alone
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or immunotherapy acting synergistically with chemotherapy
or radiotherapy that has caused the difference.
DESIGN OF FUTURE TRIALS OF IMMUNOTHERAPY
Our results suggest that specific autologous immuno¬
therapy may delay tumour recurrence in patients with stage I
lung cancer especially those who are capable of mounting
an immunological response to antigenic material. This
trial started in 1975 when relatively little was known
about tumour immunotherapy. These results and numerous
reports from the literature suggest that a further trial
starting this year should have the following modifications:
Timing, duration and nature of immunotherapy
The aim of treatment is to stimulate the immunological
system to destroy small populations of tumour cells that
are disseminated before, during or just after operation
or that are left behind at the operation site. The time
of maximum danger is the operation itself when tumour cells
may be discharged into the blood (Kuper and Bignall, 1966)
and one to two weeks after operation when immunological
function is depressed. It thus seems that immunotherapy
should be started before operation. Although both auto¬
graft and control patients in this study were "primed"
with BCG. before operation, the only current trial of
preoperative immunotherapy is that of intralesional BCG.
by Holmes (1981).
Other studies have shown promising clinical results
at 1 and 2 years after operation but no effect of immuno¬
therapy on survival and freedom from tumour recurrence
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thereafter (e.g. Edwards and Whitwell, 197^+5 Pouillart,
Palangie and Huguenin, 1979)* Although immunotherapy
was given for 18 months by Pouillart et al. (l979)> in
many studies immunotherapy was given only during the
immediate postoperative period. In our study the duration
of immunotherapy was limited by the volume of autologous
tumour cells available. In the intrapleural studies,
surgical considerations suggest that repeated injections
at the site of the operation might produce more complic¬
ations than those already encountered (Law et al., 1981).
A future trial should therefore consist of immunotherapy
prolonged over one or 2 years after operation to reduce
the risks of late relapse.
These two considerations rule out the use of auto¬
logous tumour cells. This treatment has the theoretical
advantage that these cells are not destroyed by ordinary
transplantation rejection mechanisms and so may have
more time and opportunity to evoke an immunological attack
on tumour cells left behind at operation. On the other
hand, allogeneic cells possessing different tumour-
associated antigens may evoke more immunological reaction
in general. With modern methods of storage, these cells
can be obtained in relatively unlimited supplies in
large centres so that injections of cells or extracts
could be given before and at regular intervals after
operation over a couple of years. The cells should be
rendered more immunogenic with the appropriate enzymes
(e.g. neuraminidase). Despite claims for C. parvum, BCG.
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is more widely available and there is more evidence of
its effectiveness as an adjuvant in patients (Mathe" et al.,
1969b). By percutaneous administration it can be given
repeatedly without undue side-effects although the dose
may need to be modified in tuberculin sensitive patients.
Route of immunotherapy
The value of local treatment is still unproven. In
the study of McKneally, Maver, Kellar and Lininger (1978)
intrapleural BCG. considerably reduced the incidence of
local recurrence. However relapse after successful
resection of lung cancer is more often due to distal
metastases (e.g. in 70% of relapsed cases, Bourgeon,
Richelm, Lelan et al. (1980)). This fact and the inability
to give local immunotherapy repeatedly over a period of
time indicate that a further trial now would still involve
intradermal or percutaneous administration of the immuno¬
logical stimulant. However this could be combined with
a single local treatment as in some current trials (e.g.
McKneally, Maver, Bennett and Ruckdeschel, 1980).
Staging procedures
(a) Preoperative
Since the start of the original trial, more accurate
preoperative staging procedures have become widely
available. Liver, bone and CAT. scans should be done
to exclude patients with distal metastases and, in the
case of CAT. scans, to define more accurately the extent
of intrathoracic disease. Mediastinoscopy would be used
only in patients where there were doubts over the extent
of mediastinal lymph node involvement.
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(b) Survival and pathological
Careful assessment of the surgical stage has always
been the practice in the units involved in this study.
Nevertheless it may be that dissection out of all known
groups of mediastinal lymph nodes should be attempted
in future. This might improve the clinical results as
well as leading to more accurate staging. The operation
would be more prolonged but there is no evidence that
such dissection causes increased morbidity or mortality.
Randomisation
In this study stratification of patients was carried





It seems likely that some of the discrepancy in results
between different groups of workers and the marginal
benefits of immunotherapy described by some workers is
due to differences between samples of patients concealed
within broader divisions such as non-squamous cell carcinoma
and stage I tumours. It may be that stratification
according to TNM. subdivisions of stage I to III should
be included.
There is some evidence that certain groups of patients
are more likely to respond to immunotherapy, e.g. tuberculin
positive patients (Jansen et al., 1980) DNCB. positive
patients (Chen, Ogino, Wada, Matsumoto et al., 1980) and
those with an acceptable level of active T rosette forming
171
lymphocytes (Kerman and Stefani, 1978). In future trials
of immunotherapy, stratification might take account of
some criterion of immunological reactivity measured before
operation.
The corollary of such multifactor stratification is
that series of patients studied should be large (several
hundreds) in order that statistically significant benefits
of treatment could be recognised. This implies the need
for multicentre trials such as those already in progress
in North America and Europe.
Immunological measurements
One of the weaknesses of most published investigations
of immunotherapy has been their failure to correlate
clinical results with immunological measurements. More
success in this field may be achieved with the development
of better techniques of measuring macrophage function.
It will also be important to assess the in vitro effect
of the patients' lymphocytes and macrophages on their own
tumour cells. The implications for organisers of such
projects is that more funding is needed to provide
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The previous sections have dealt with immunological
methods of treatment of lung cancer. This section deals
with the immunological measurement of circulating tumour
markers in the diagnosis and discusses their present place
in assessing the prognosis and response to treatment.
A classification of these markers is given in Table h.
SERUM ANTIGENIC MARKERS
One of the most interesting discoveries in the field
of cancer diagnosis has been the finding that certain
antigenic substances found in foetal and embryonic tissues
are also present in high concentrations in malignant
tumours. In 1963 Abelev, Perova, Khramkova et al. described
the isolation of a-foetoprotein (AFP.). Two years later
came the first description of carcinoembryonic antigen
(CEA.) by Gold and Freedman (1965)* CEA. is a glyco¬
protein, MW. approximately 200,000 daltons which elutes
between IgG and IgM on a Sephadex-G 200 column (Terry,
Henkart, Coligan and Todd, 197^)* Thomson, Krupey,
Freedman and Gold (1969) developed a radioimmunoassay
for this and showed that 35/36 patients with large bowel
tumours had detectable levels in the serum. Subsequently
measurement of CEA. has become established as a useful
test in detecting recurrence of bowel cancer following
surgery.
Most estimations of oncofoetal antigens involve
radioimmunoassay. In the case of CEA., anti-CEA. anti¬
serum raised in animals is added to the test serum





















Table 34. Antigenic markers in lung cancer.
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labelled CEA.. Unlabelled CEA. in the patient's serum
competes with the labelled CEA for the antibody binding
sites. Antibody-bound CEA. is precipitated chemically
using zirconyl phosphate (Hansen, Lance and Krupey, 1971)
or with an anti-immunoglobulin (double antibody technique)
(Egan, Lautenschleger, Coligan and Todd, 1972). Comparison
of the percentage of labelled CEA. bound in the test serum
with the percentage bound in the presence of known amounts
of CEA. allows quantitation of CEA. in the sample.
CEA. levels have now been measured in several series
of patients with lung cancer (Table 35)• The two main
types of radioimmunoassay used are:
1. the perchloric acid technique (Hoffman La Roche test)
(Hansen et al., 1971 )•
2. the direct radioimmunoassay method (Egan et al♦, 1972).
In this higher values are obtained depending on whether
they are referred to serum-based standards.
Diagnostic value of antigenic markers
The disadvantage of CEA. as a reliable diagnostic
screening test in lung cancer is that elevated levels
have never been found in more than 75% of" unselected
cases (Table 35)• In patients with resectable tumours
the incidence of raised CEA. levels was much less e.g.
1 h°/o (Ford, Newman and Anderson, 1979) and 18% (Concannon,
Dalbow, Hodgson et al., 1978b). Previous reports have
shown elevated levels of pregnancy associated a2 glyco¬
protein (a^-PAG.) in 60% (males only, Gropp, Lehmann,
Bauer and Havemann, 1977)> the P subunit of human chorionic
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Rochman, Hunter et al., 1979)* While this rate of positive
tests is far too low to allow the use of individual markers
as diagnostic screening tests, combination of tests might
produce a more accurate method of diagnosis. For this
reason, we decided to measure five antigenic markers in
recently diagnosed lung cancer cases and to assess the
value of combined measurements in diagnosis.
METHODS
Patients
197 patients were studied in three Glasgow hospitals.
Samples of blood were taken from the patient on first
attendance at the chest clinic or shortly after admission
to the ward. It will be noted that even at this relatively
early stage of investigation nearly half the patients had
clinical or radiographic evidence of metastases.
All the controls were patients attending a chest clinic
or admitted to the ward for investigation or follow-up
of non-malignant pulmonary or cardiac disease. 27 out
of 70 (39%) suffered from chronic bronchitis, asthma
and/or emphysema and 21 (30%) from healed or active
pulmonary tuberculosis. The ages and sex of the lung
cancer patients and controls were similar (Table 36).
None of the patients or controls were taking cortico¬
steroids or other immunosuppressive drugs. Although the
smoking habits of the controls were not recorded, they are
likely to have been similar to those of the lung cancer
patients in view of the high proportion of patients with
chronic obstructive airways disease and of our findings




Males: Number 158 52
Mean age (years) 63. 4 60.7
Range of ages (years) 26-85 42-86
Females: Number 39 18
Mean Age (years) 61.3 59.4
Range of ages (years) 45-83 46-71
Table 36. Age and sex of lung cancer patients and controls.
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Laboratory Methods
Serum was separated from the blood samples and was
stored at -20°C until the relevant measurements could be
made. The laboratory methods used are detailed in
Table 37-
RESULTS
Only 3 of 70 control patients had CEA. levels greater
than 40 ng/ml and none had levels greater than 100 ng/ml.
In contrast, 3^+ of the 197 lung cancer patients had
elevated levels and 23 had levels in excess of 100 ng/ml.
The mean values for CEA. were significantly higher in the
lung cancer group compared with controls (Table 38).
As the majority of lung cancer patients in the West
of Scotland smoke cigarettes, suffer from chronic bronchitis
and/or have had pulmonary tuberculosis, we have calculated
the number of lung cancer patients with antigenic marker
levels greater than the upper 95th percentile of the
controls. In this way we hoped to estimate the extent to
which elevated marker levels could be attributed solely
to the tumour.
Separate levels for pregnancy-associated a^-glycoprotein
(a^-PAG.) were calculated in males and females because of
the difference in normal values of this marker between
the sexes. Because many patients had serum concentrations
below the minimum detectable levels, mean values for
markers other than CEA. could not be calculated.
The overall prevalence of elevated levels of


























Range of CEA. ng/ml 11.2 - 66.0 5.0 - 720.0
Mean CEA. ng/ml 2k. 2 52. 6
Number with CEA. > 40 ng/ml 3 (4%) 3^(17%)
Table 38. Serum CEA. levels in lung cancer patients and
controls.
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prevalence was higher than 20% in certain subgroups
where the total number of cases was small (Table 39,
from Burt, Ratcliffe, Stack et al. , 1978). 38%> of controls,
3>0%> of patients with localised disease and k-S>%> of patients
with metastases had undetectable levels of AFP. in the
serum. In no control patients could HCG. be detected
and measurable levels were found in only 2/58 patients
with localised disease and 5/55 with metastases.
When the results for different markers were combined,
some concordance of elevated HCG., AFP., and casein levels
was found. Thus of 7 patients with elevated HCG. levels,
one also had elevated CEA.; of 6 with elevated casein,
2 had elevated CEA; and of 2 with elevated AFP., one
had elevated CEA..
In contrast there was a negative correlation of CEA.
and a^-PAG. (r -0.22, p < 0.05, n = 89). All patients
with elevated CEA. levels had normal cx^-PAG levels and
vice versa (Table ko) .
The mean CEA. level was significantly higher in
patients with metastases than in those with localised
disease (Table ^l). Similarly the prevalence of a raised
CEA. level was greater in patients with metastatic disease.
This pattern was not confirmed for other markers (Table 39) •
Figure 3^ shows the CEA. levels in the individual
patients with a histological diagnosis. There is no
clear relationship between histology and CEA. concentration.
However this series contained only 2 patients with adeno¬





































Table39*Prevalenceofe vatedlev lsofa tigenicmarkersiu gancer.
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240 0.2 19.4 86
43 0.2 29.3 155
395 26. 0 18.0 128
238 25.0 10.8 133
195 0.2 24.0 96
193 9.0 30.0 108
i4o 57-0 16. 7 135
520 12.0 15. 2 250
55 0.2 24.0 105
220 0.2 14.8 127
135 0.2 38.0 166
340 0.2 00•r>CM 131
45 50.0 10. 8 72
42 22. 0 15.0 118
195 20.0 20.0 80
42 18.0
Table 40. Discordance between elevated CEA. and a^-PAG.




Mean CEA. (ng/ml) 32 7b
Range of CEA. (ng/ml) 5 - 280 8 - 720
Number 40>ng/ml 12 (12%) 22 (23%)








SMALL LARGE CELL SQUAMOUS ADENO-
CELL ANAPLASTIC CELL CARCINOMA
Fig. 34 Serum CEA values in unselected lung cancer
patients according to histology.
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elevated CEA. levels have been reported (Ford, Newman
and Lakin, 1977; Bisset, Roux, Sauvan et al., 1978).
DISCUSSION
Value of antigenic markers in diagnosis
CEA. is the principal serum antigenic marker measured
in lung cancer. In the majority of reports, elevated
levels have been found in more than half of the patients
studied when these have been compared with normal controls
(Table 35). Our results show a much lower prevalence of
raised serum CEA. and are closer to those of Ford et al.
(1977) and Bisset et al. (1978). This di screpancy is not
due to the methods used. The perchloric acid extraction
method (Hansen et al., 1971) was used by three American
groups (Vincent, Chu, Fergen and Ostrander, 1975;
Broder, I98O; Waalkes, Abeloff, ¥00 et al., 1980) whereas
others, including all the European groups, used a double
antibody direct radioimmunoassay (RIA.). Values of
2.5 ng/ml and 5 ng/ml in the former are roughly the
equivalent of values of 20 and ^-0 ng/ml in the latter. It
can be seen that a similar prevalence of above normal CEA.
values was obtained by workers using the perchloric acid
extraction method (Vincent et al., 1975; Waalkes et al.,
1980), those using the direct RIA. method (Gropp, Lehmann
and Havemann, 1979a) and those using an automated in¬
direct RIA. (Paone, Kardana, Rogers et al., 1980).
A major factor in this discrepancy is undoubtedly
the selection of the reference value. Vincent et al.
(1975) derived this from levels in normal blood donors.
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These might be expected to be healthier than a population
of lung cancer patients and to have a lower prevalence of
cigarette smoking. Elevated levels of CEA. are commoner
in smokers (Stevens, Mackay and Busselton Population
Studies Group, 1973) and in patients with benign pulmonary
disease (Hansen, Snyder, Miller et al. , 1974) • Lung
cancer patients are usually smokers (81% in the immuno—
reactive hormone study, see below) and frequently also
suffer from chronic bronchitis. Hence it is more logical
to use smokers with benign pulmonary disease as controls.
In Table 35, it can be seen that the prevalence of
elevated CEA. levels was much reduced in three series when
the reference value was derived from smokers and/or patients
with benign diseases. Had we taken 20 ng/ml as the upper
limit of normal, as did Grigor, Detre, Laurence et al.
(1975), 64% of our patients would have had elevated levels
of CEA..
Even taking the series with the highest percentage of
CEA. levels above those of smokers or patients with benign
pulmonary (55%, Broder, 1980) it is clear that serum CEA.
estimation falls well short of the requirements for a
diagnostic or screening test.
CEA. has also been estimated in bronchial secretions
aspirated at bronchoscopy (Aubanel, Milano, Schneider
et al., 1978). However the prevalence of raised levels
was much higher in patients with bronchoscopically visible
and therefore already diagnosed tumours than in those
with more peripheral lesions. Moreover raised levels of
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CEA. also occurred in benign pulmonary inflammatory
conditions. Despite the fact that serum and tissue levels
of CEA. are usually highest in adenocarcinomas (Ford et al.,
1977; Sun, Bennett, Carpentier and Terry, 1976), of which
a higher proportion are peripheral tumours, measurement
of bronchial aspirate CEA. was of little help in diagnosis.
The value of measuring pleural fluid CEA. was assessed by
Thomson, Rana and Ratcliffe (1979)• From their own
results and those of five other groups they concluded
that it was a useful addition to pleural biopsy and fluid
cytology with a test sensitivity around kO°/o.
As the prevalence of raised serum levels of single
markers was too low for them to be individually useful in
the diagnosis of lung cancer, the value of combining
measurements of several markers has been considered. A
surprising finding has been the negative correlation of
CEA. with a^-PAG., a high MW. glycoprotein found especially
in pregnancy but also found in patients of both sexes with
breast and lung cancers (Stimson, 1975)* This negative
correlation was not due to oc^-PAG. acting as a carrier
for CEA. (Burt et al., 1978) and no explanation for it
has yet been discovered. One or more of the 5 markers
was elevated in k6°/o of those patients who had k or more
markers measured. This contrasts with elevation of one
or more of CEA., P-HCG. and casein in 76% of patients
studied by Reddy et al. (1979)* However both results
fall short of the prevalence necessary to make even this
combination of tests useful in the diagnosis of lung
cancer.
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AFP. is not a useful tumour marker for lung cancer
having been found in the serum of none of the patients
of Gropp et al. (1977) and in only 3% by Grigor et al.,
(l975)- Similarly as other workers have found elevated
levels of HCG. in only 3^°f° (Gropp et al. , 1980), 16%
(Reddy et al. , 1979) and 12% (Broder, 1980), our finding
of raised levels in only 6% confirms the uselessness of
this antigenic marker in the diagnosis of lung cancer.
Serum casein is a normal protein constituent of
milk. Initial attempts to measure blood levels were
made in pregnant and lactating women. The finding of
significant levels in all lactating women led to the
investigation of this protein in patients with breast
cancer in whom 1 in 7 had detectable levels. This led
to speculation as to whether the substance could be
produced by non-endocrine tumours and significant levels
were found in all lung cancer patients tested (Hendrick
and Franchimont, 197^-) • ^2 of the 197 patients in our
series were tested for this antigen but the levels were
significantly raised in only 14%. Thus while further
evaluation using more sensitive assay techniques would
be worth considering, at present serum casein is not
likely to be of major value in the diagnosis of lung
cancer.
Prognostic Value of Antigenic Markers
Serum antigenic markers may be of value in assessing:
1. The stage and resectability of tumours
2. The response to treatment
3. The recurrence and progression of tumours.
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Radical resection of lung cancer is undertaken in
patients believed preoperatively to have Stage I and
Stage 2 tumours. Most surgeons do not operate on patients
in whom clinical and radiographic investigations have
suggested that their tumour is Stage 3« It would thus be
helpful if measurement of CEA. discriminated between
Stages I and 2 and Stage 3« Although Dent, McCulloch,
Wesley-James et al. (1978) did find a mean CEA. level of
7•3 ng/ml in inoperable cases compared with 3*1 ng/ml in
operable cases(the incidence of elevated CEA. levels in
Stage I and Stage 2 (l8%) and Stage 3 (25%) was not
significantly different in another study (Concannon et al.,
1978b). However a very considerably raised CEA. in an
apparently operable case does suggest a poor prognosis.
Only two patients with CEA. greater than 10 ng/ml (upper
limit of "normal" 2.5 ng/ml) in the series of Vincent,
Chu and Lane (1979) survived their operation by more
than two years. Similarly Ford et al. (1979) found that
11 of 14 patients with pre-operative levels greater than
kO ng/ml developed metastases or had locally ineradicable
tumour.
In a larger non-surgical series, Gropp, Havemann
and Scheuer (1980) found CEA. levels greater than 10 ng/ml
(upper limit of "normal") in only 16% of patients with
disease confined to one hemithorax and the ipsilateral
cervical nodes but in 82% of patients with more dis¬
seminated disease.
Serum levels of other markers have also been of only
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limited value in assessing the stage of the disease.
Thus K-casein and P-HCG. did not help to distinguish
between and tumours, and lymph node involvement,
or patients with and without distant metastases (Reddy
et al., 1979)" On the other hand, measurements of serum
haptoglobin, orosomucoid and C-reactive protein correlated
with tumour size (Bradwell, Burnett, Newman and Ford,
1979) though tumour size was not related to prognosis.
However it was found that patients in whom these serum
factors were higher than the mean level for their size
of tumour had a poor prognosis.
Circulating levels of antigenic markers can also
reflect the effects of treatment. In patients with
elevated levels of CEA. before operation, the concentration
drops to normal levels within five days of tumour resection
(Vincent et al., 1979) and after chemotherapy and radio¬
therapy (Gropp et al., 1979a).
In patients in whom CEA. level does not fall after
radiotherapy, tumour progression is likely to be occurring.
Moreover elevation of previously normal CEA. may precede
clinical and radiographic evidence of tumour recurrence
(Gropp et al., 1980).
In view of the apparent relationship between antigenic
markers and tumour size (Bradwell et al., 1979) and the
evidence that immunotherapy is likely to be effective
only where the tumour cell population is small, one
would expect antigenic marker levels to give some guide
to the likely response to immunotherapy. This has been
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confirmed by Gautier, Baron, Huguenin et al. (1978).
They found that in 19 of 27 patients with inoperable
squamous cell carcinoma who had normal CEA. levels,
there was evidence of tumour response to percutaneous BCG.
given three times a week for three weeks compared with a
response in only 1 out of 12 patients with elevated
CEA. levels.
Circulating immunoreactive hormones in lung cancer
Other potential immunological markers for lung cancer
are the immunoreactive hormone ACTH. and related peptides.
In 1928 Brown described the occurrence of thirst,
anorexia and weakness in a 4-5 year old woman. She was
found to be pigmented and to have other clinical features
of Gushing's Syndrome including glycosuria. Her condition
deteriorated and at autopsy she was found to have a small
cell carcinoma of the lung.
The occurrence of a Cushing-like Syndrome in association
with lung cancer subsequently became recognised as an
occasional non-metastatic complication. Estimates of its
incidence in unselected series of cases have included
0.5 to 2% (Yesner, 1978), 0.5% (Azzopardi, Freeman and
Poole, 1970) and 0.4% (Rassam and Anderson, 1975)' The
vast majority of these cases have occurred in association
with small cell carcinoma.
That this syndrome was due to excessive ACTH.
production by the tumour was eventually established by
Meador, Liddle, Island et al. (1962). They found elevated
concentrations of ACTH. in the tumour tissue and in the
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plasma of five patients, three of whom had small cell
carcinoma of the lung. The urinary 17-hydroxycortico-
steroids were elevated and dexamethasone did not reduce
their concentration.
Meador et al. (1962) used a bioassay of ACTH. but
nearly all the work in the past 12 years has been based
on immunological methods. One of the earliest descriptions
of this approach was that of Berson and Yalow (1968).
In their radioimmunoassay, the isotopically labelled
peptide under investigation (e.g. ACTH.) is bound to a
specific antibody raised in experimental animals (e.g.
guinea pigs). Competitive inhibition of the binding of
this specific antibody is measured when the plasma or
serum under test is added. This competitive inhibition
is compared with that occurring when standard solutions
of ACTH. are added. The ratio of bound to free ACTH.
is calculated for the test plasma or serum and the absolute
ACTH. value is read off from curves prepared using the
standard solutions.
Berson and Yalow found that ACTH. levels in plasma
were lower in the evening. They were depressed by
dexamethasone and increased by hypoglycaemia, shock and
surgery under general anaesthesia.
Armed with a comparatively simple assay method, the
same group of workers measured levels of ACTH. in pituitary
gland, tumour tissue and plasma. An early discovery was
that the nature of the ACTH. varied (Yalow and Berson,
1971)• The predominant form in tumour tissue and the
plasma of tumour patients was not the normal pituitary
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1-39 ACTH. but a large molecular weight more acidic
peptide. Referred to as "big ACTH", this had a molecular
weight of approximately 20,000 daltons (Wolfsen and Odell,
1979)* On filtration through Sephadex G50 columns, its
elution volume lay between human growth hormone M.W.
20,000 and serum albumen M.W. 68,000 (Yalow and Berson,
1973)* Big ACTH was rapidly broken down to 1-39 ACTH. on
exposure to trypsin (Gewirtz, Schneider, Krieger and Yalow,
197^a)• Its immunoreactivity was indistinguishable from
that of 1-39 ACTH.. However, while the biological and
immunological reactivities of the latter were similar, the
biological activity of big ACTH. was less than h°/o of its
immunological activity. This was shown by measuring its
ability to stimulate corticosterone production by the
adrenal glands of Sprague-Dawley rats.
One result of this low biological activity is that
ectopic big ACTH. has relatively little effect on the
adrenal cortex. Plasma Cortisol was not higher in lung
cancer patients with elevated ACTH. levels than in lung
cancer patients with normal ACTH. levels (Gropp, Havemann,
Scheuer and Grun, 1979b). Consequently feedback suppression
of pituitary ACTH. production would not be expected. Thus
the overall effect of ectopic ACTH. production by tumour
is an increase in total circulating immunoreactive ACTH..
The predominance of "big ACTH." in tumour tissue
and the circulation of patients with lung cancer suggests
that, while neoplastic cells have the ability to manufacture
the necessary amino acid sequences to form ACTH., they
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lack the enzymes which can trim the precursor large
molecule into 1-39 ACTH. (Yesner, 1978).
Circulating ACTH levels
The finding of elevated plasma ACTH. in a large
proportion of cases (Ayvazian, Schneider, Gewirtz and
Yalow, 1975) raised the prospect of using this measurement
in the early detection of lung cancer. Since then a
number of other workers have measured circulating ACTH.
levels in a variety of lung cancer patients and the results
are summarised in Table 42. All groups have used radio¬
immunoassay techniques based on that already described
(Berson and Yalow, 1968). With this method, ACTH. is
detectable at a level 10-20 ng/l (normal range 10-80 ng/l).
Thus most workers have expressed their results in terms
of the prevalence of plasma or serum concentrations above
a given value. In some instances this absolute value
has been fixed arbitrarily. In others it has been
determined in relation to values for healthy laboratory
controls (Hansen, Hansen,Hirach et al♦, 1980) or normal
subjects and patients with minor illnesses (Wolfsen et al♦,
1979)» This absolute value has varied from 76 to 150 ng/l
but as the methods of radioimmunoassay used vary between
laboratories, the variation in absolute value is not of
great significance.
The reports from the Mount Sinai Hospital, New York
(Gewirtz and Yalow, 1974; Ayvazian et al., 1975) showed
that ACTH. levels above the arbitrary upper limit of
normal were recorded in about one third of patients with





























































also found immunoreactive ACTH. in lung tissue from
smoking dogs with atypical epithelial changes. Moreover
Yalow (1979a) reported that two patients from this group
who subsequently died had precancerous epithelial changes
at autopsy but no evidence of lung cancer. As the
population at risk of developing lung cancer consists of
male smokers over kO, many of whom have already developed
chronic bronchitis, the value of measuring circulating
ACTH. in early diagnosis can only be estimated by relating
the results from lung cancer patients to those of age and
sex matched patients with chronic pulmonary disease and
similar smoking habits.
In our study we have used as controls patients
attending hospital with non-malignant pulmonary disease.
We have taken as the upper limit of normal the upper limit
of the range of values from these patients. In this way
we have hoped to assess the frequency with which circulating
ACTH. is raised due to secretion by tumour tissue.
METHODS
(a) Patients and Samples
13^ patients attending the out-patient department
or admitted to hospitals in Marburg and Glasgow during
1978 and 1979 were included in this study (Ratcliffe,
Podmore, Stack et al., 1981). The diagnosis of lung
cancer was confirmed by bronchial or pleural biopsy,
biopsy of enlarged lymph nodes or other metastases,
sputum cytology or eventually at autopsy. Patients in
whom the tumour was confined to one hemithorax and
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ipsilateral mediastinal and cervical lymph nodes were
considered to have localised disease. More widespread
disease was classified as extensive. Tumours were
divided into small and non-small cell groups according to
the WHO classification by pathologists who were unaware
of the clinical details and laboratory findings.
The controls were patients attending a Glasgow hospital
with non-malignant pulmonary disease (Table ^3)* They
were matched for age and sex with the Glasgow lung cancer
patients. None of the patients or controls were taking
corticosteroid drugs and none suffered from overt (hashing's
syndrome. 81% of the Glasgow lung cancer patients were
smokers compared with 52% of the controls.
10 ml. samples of venous blood were withdrawn between
9 and 10 a.m. into heparinised or plain bottles. These
were immediately centrifuged and the serum or plasma
snap frozen and stored under dry ice (-20°C) until radio¬
immunoassay could be performed.
Laboratory Methods
Unextracted plasma and serum ACTH concentrations
were measured using a double antibody radioimmunoassay.
Antiserum against 1-39 human ACTH. was raised in rabbits
and labelled 1-39 human ACTH. was used for iodination.
The assay was validated by comparing ACTH. values so
obtained with those found using a well-validated N-terminal









Total number 30 113 21
Number of males 23 99 18
Mean age 62 63 66








Table 43* Clinical details of control and lung cancer
patients in study of circulating immunoreactive
hormones.
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Extracted plasma ACTH. levels were measured using
porous glass (Ratcliffe and Edwards, 1971)* This
selected against high molecular weight ACTH. components
and C-terminal fragments of ACTH. so that the assay was
relatively specific for 1-39 ACTH.. ACTH. was assayed
as described by Rees, Cook, Kendall et al. (1971) using
iodinated human 1-39 ACTH. as tracer and antiserum
directed towards the biologically active 1-2*7 region of
the molecule. This was standardised against natural human
ACTH.. The limit of detection was 10 ng/l.
PMSH immunoactivity was assayed by the method of Gray
and Ratcliffe (1979) standardised with synthetic human
PMSH (Ciba) using an antiserum which cross reacts equally
on a molar basis with human PMSH, PLPH and ^ LPH. There
was no cross reaction with ACTH. and its fragments, P
endorphin or enkephalins. The limit of detection was
10 ng/l.
LPH immunoactivity was assayed by the method of
Podmore, Wilson, Cowden et al. (1979) using iodinated
PLPH and an antiserum which cross reacts equally on a
molar basis with human P and y LPH. There was no cross
reaction with human PMSH, ACTH. and its fragments,
P endorphin or enkephalins. The assay was standardised
against purified human PLPH. The limit of detection was
80 ng/l.
RESULTS
It can be seen from Table 73 that the controls and
patients were of similar ages and sex ratio. Two thirds
of the controls suffered from chronic bronchitis or
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asthma and seven were receiving treatment for pneumonia
or pulmonary tuberculosis. The control values were all
similar to the laboratory reference values.
When the unextracted method was used, serum levels
were rather lower than plasma levels. This was shown by
the difference in the range of ACTH. concentration in
serum and plasma. Similarly 77% of serum concentrations
of ACTH. but only 58% of plasma concentrations in all
patients were less than 30 ng/l (Table kk).
When the extraction method was used, no patients had
plasma ACTH. or (3-MSH. concentrations above the control
range and in only one patient was the concentration of
LPH. raised (Table •
The Marburg group contributed a relatively large
proportion of the small cell carcinoma patients in whom
serum rather than plasma levels were measured. The overall
incidence of elevated ACTH. levels was 7% for plasma and
17% for serum. For small cell carcinoma these values
were 17% and 2k°/o respectively and for non-small cell
carcinoma 0% and 3%•
There was a higher proportion of elevated ACTH.
concentrations in patients with extensive (32%) as opposed
to limited (12%) small cell carcinoma. No such difference
could be detected in the small numbers of non-small cell
carcinoma with elevated ACTH. levels.
DISCUSSION





















Limited 6 0 0 25 3 12
Extensive 12 3 25 38 12 32
All cases 18 3 17 63 15 2b
Non-small cell
Limited 20 0 0 20 0 0
Extensive 6 0 0 10 1 10
All cases 26 0 0 30 1 3
All lung
cancer cases bb 3 7 93 16 17
Table bb. Prevalence of raised total ACTH. levels in
serum and plasma in patients with lung cancer.
The control ranges were < 20-73 ng/l for plasma





















































Table45*Prevalenceofelevat dplasmal velsofACTH.,P-MSH.ndLP .u ingxtraction method.Controlrangeswere<10-73ig/lf rACTH.,14-62ng/lf rMSand<80-341ng/lforLPH.
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1. A relatively low prevalence of raised serum and plasma
ACTH. in lung cancer.
2. Elevation of circulating ACTH. predominantly in small
cell carcinoma, especially where this was extensive.
Prevalence of raised ACTH. levels in plasma and serum
The prevalence of raised ACTH. levels in this study
was similar to that of three other European groups (Gropp
et al., 1980; Hansen et al♦, 1980; Torstensson, Thoren
and Hall, 1980) but much less than that found by two
American groups (Ayvazian et al., 1975 and Yalow, Eastridge,
Higgins and Wolf, 1979; Wolfsen et al., 1979)> (Table h2).





4. Definition of the upper limit of "normal".
Samples
Most workers have studied plasma levels. However
Gropp et al. (1980) also measured some serum concentrations
of ACTH.. Serum levels were also measured in some patients
in the current study. As expected serum levels were
rather lower both in normal and lung cancer patients.
This may be due to the destruction of some ACTH. during
the clotting process. As the other European workers
measured plasma levels, this detail cannot explain the
discrepancy between American and European results.
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In our study samples were withdrawn between 9 and
10 a.m. Circulating ACTH. levels are known to be highest
at between 8 and 10 a.m. and to be lower later in the
day in normal subjects. Although the times of withdrawal
of specimens are not clearly stated in some reports,
Ayvazian et al. (1975) withdrew their specimens after
3 p.m. If time of day were the cause of the discrepancy,
their results would be expected to be lower than those
in this investigation.
Laboratory Methods
In all the studies ACTH. and other hormones were
measured by a radioimmunoassay technique in which antibodies
to the hormone were raised in animals. These antibodies
react to a certain sequence of amino acids in the ACTH.
molecule adjacent to the N terminal. However the specificity
of the antiserum used in different laboratories is likely
to have varied. Some antibodies may also react with C
terminal elements in "big ACTH.", related peptide hormones
(e.g. (3-MSH. and LPH. in the ACTH. assay) and other serum
proteins.
The specificity of the radioimmunoassay can be
increased if the plasma is "extracted". This "extraction"
method measures mainly physiological or 1-39 ACTH.. As
this hormone comprises only 20-^0% of ACTH. in lung
tumours (Yesner, 1978) a lower prevalence of raised ACTH.
concentrations would be expected when this method is
used. This was indeed the finding of our own study
(Table ^5) but it also does not explain the discrepancy
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with the American results. Indeed Wolfsen et al. (1979)
found raised levels of ACTH. in Jb'/c of lung cancer patients
using the "extraction method". Their results were
similar to those of Yalow et al♦ (1979) who studied
unextracted plasma.
Patients
(a) Histology of the tumour
As the majority of lung tumours associated with overt
Gushing's syndrome are small cell carcinomas, the prevalence
of raised ACTH levels was compared in small and non-small
cell carcinoma (Table bb). In this study and in those of
Gropp et al. (1980) and Hansen et al. (1980) circulating
ACTH. levels were raised in very similar proportions of
small cell carcinoma patients but in the series of
Ayvazian et al. (1975) "the levels were raised in the only
two small cell carcinoma cases. There were no small cell
carcinomas in the surgical series of Yalow et al♦ (1979)
as it was not current practice to operate on patients
with this tumour.
The most striking discrepancy between the American
and European results was found in non-small cell carcinoma.
Whereas the New York workers found elevated ACTH. levels
in 72°/o of cases, the prevalence was only 3% and 10°/c
respectively in the current report and in the series of
Gropp et al. (1980).
(b) Size of tumour
Ayvazian et al. (1975) calculated that either a tumour
must be large or that it must have more active ACTH.
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production than the pituitary gland if circulating ACTH.
levels were to be elevated. Tumour size is only one
facet of tumour stage which also reflects local and
distant spread. If the tumours in the series of Wolfsen
et al. (1979) and Yalow et al. (1979) were larger or more
widespread than those in the other series, the higher
prevalence of raised ACTH. levels would be explained.
However the reverse is the case since Yalow et al. (1979)
studied only surgical cases, most of whom would have
stage I or stage 2 tumours. Moreover many of the patients
of Wolfsen et al. (1979) were diagnosed on the basis of
peripheral radiographic opacities. In contrast, in the
current study and that of Gropp et al. (1980), the series
were unselected and contained patients with extensive
disease.
Definition of the upper limit of "normal"
The prevalence of raised levels of circulating ACTH.
clearly depends on the upper limit of "normal". How
this limit was defined by seven groups of workers is
summarised in Table k2. Only Gropp et al. (1980) used
age and sex matched controls. In our own study and in
that of Torstensson et al. (1980) the reference value
was derived by measuring circulating ACTH. concentrations
in patients with benign pulmonary disease and in both
these studies the age ranges of the lung cancer and
control patients were similar.
Gewirtz et al. (197^-) found ACTH. 1eveIs above an
arbitrary reference value of 150 ng/l in 31% of" patients
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with chronic obstructive pulmonary disease. As a large
proportion of lung cancer patients also suffer from this,
their reference value was set too low as was that of
Wolfsen et al. (1979). This error may explain much of
the discrepancy between the American results and those
of Torstensson et al. (1980) and the current investigation.
Predominance of small cell carcinoma in patients with
raised circulating ACTH. levels
In this study, serum ACTH. levels were elevated in
2k'fo small cell carcinoma but only 3% non-small cell
carcinoma patients. This finding confirms previous
descriptions of the association between elevated ACTH.
levels in tissue and plasma or serum and small cell
carcinoma.
In early reports of the ectopic ACTH. syndrome (Brown,
1928; Meador et al., 1962) all four patients with lung
tumours had small cell carcinomas. Moreover, in a review
of the literature, Broder (1979) found that 80/95 patients
with this syndrome in whom histology had been recorded
suffered from this histological type of tumour. In series
of 185 (Azzopardi et al., 1970) and 280 (Rassam and
Anderson, 1975) unselected lung cancer patients, the two
patients with this syndrome both had small cell carcinoma.
Moreover, Richardson, Greco, Oldham and Liddle (1978)
estimated that this syndrome occurred in 7% of all
patients who developed small cell carcinoma.
Others have confirmed that in patients with lung
cancer who do not have overt Gushing's syndrome, elevated
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ACTH. levels are more prevalent in small cell carcinoma
(Gropp et al., 1980). Neither these workers nor Hansen
et al. (l980a) found any relationship between ACTH. levels
and the clinical stage of the disease. However our study
did show that elevated circulating ACTH. levels in small
cell carcinoma were more prevalent in patients with
extensive disease.
If the number of tumour cells is a function of the
extent of the tumour, this finding is compatible with the
belief that in small cell carcinoma ectopic ACTH.
originates from the tumour cells. Support for this belief
also comes from the work of Bertagna, Nicholson, Sorenson
et al. (1978) who found a 1 inear relationship between the
number of human small cell carcinoma cells during the
first three days of cell culture and the concentration of
ACTH. in the culture medium. A possible site of storage
of this ectopic ACTH. is the secretory granules (Rees
and Ratcliffe, 197^)* Ultramicroscopic examination of
these granules shows that they are similar to those
found in typical peptide—secreting glands. Though present
in small cell carcinoma, they were more numerous in
ACTH.-rich bronchial carcinoids but were not found in
non-small cell carcinoma.
There is thus some controversy as to whether ACTH.
is actively produced in non-small cell carcinoma.
Bloomfield, Holdaway, Corrin et al. (1977) found significant
tissue levels in two patients with small cell carcinoma
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but in none of six patients with other histological types.
In contrast detectable levels of ACTH. were found in the
majority of patients with operable non-small cell carcinoma
by Yalow et al. (1979) although these workers later reported
higher tissue levels of ACTH. in small cell carcinoma
(Yalow, 1979b). However Ratcliffe and Podmore (1979)
suggested that the ACTH. in non-small cell carcinoma could
either indicate the presence of carcinoid or small cell
tissue within such tumours or, in the case of levels —n—
1 ng/g, retained circulating hormone or non-specific
effects in the assay.
Is tumour tissue the only source of ectopic ACTH.?
The finding of raised levels of plasma ACTH. in 31 °/° of
controls with chronic obstructive pulmonary disease led
Gewirtz and Yalow (197^-) to consider whether damaged
normal lung could produce ACTH.. They failed to prove
this in normal human lung tissue taken at operation and
in normal lung tissue taken from a dog exposed to cigarette
smoke. However they did find elevated levels of ACTH.
in a similar dog in which precancerous epithelial changes
of the type seen in heavy smokers and lung cancer patients
were present. Moreover, Bloomfield et al. (1977) found
that ACTH. concentrations from normal lung tissue taken
from the same lobe or lung remote from the tumour
correlated closely with ACTH. levels in the tumour itself.
Hence it seems possible that cells throughout the lung
of such patients secrete ACTH. They may do so as part of
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the precancerous process or as a result of the development
of neoplasm. Such cells could be the Kulchitsky cells
which have been described in bronchial epithelium (Yesner,
1978). An alternative hypothesis is that the ACTH. is
produced by secretory granules that have migrated from
the primary tumour tissue.
ACTH. concentrations correlate closely with those of
related hormones. Concentrations of ACTH, P-endorphin
and LPH. rose in parallel in tissue cultures from small
cell carcinoma (Bertagna et al., 1978). A close relation¬
ship between concentrations of ACTH. and those of LPH
(Ratcliffe and Podmore, 1979) and P-MSH. (Gray and
Ratcliffe, 1979) have been described. These hormones
share a common hexapeptide sequence. It is now widely
recognised that many different hormones can be produced
in association with lung cancer, especially small cell
carcinoma (Rees, Bloomfield, Rees et al., 197^0 •
Value of measuring circulating ACTH in clinical practice
The European results show that plasma ACTH. levels
are raised in less than 30% of unselected small cell
carcinoma patients and in a considerably lower proportion
of non-small cell carcinoma patients. Thus this measurement
is of no value in the screening of "at risk" populations
or in the diagnosis of the individual patient.
The finding of a raised plasma ACTH level may be
helpful in assessing the response to treatment. Elevated
ACTH. concentrations fell to normal in all four small
cell carcinoma patients treated with chemotherapy by
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Hansen, Hammer and Hummer (1980). Three of these also
had objective regression of tumour. Such a response may-
occur within 10 days of a course of chemotherapy (Gropp
et al♦, 1980). Elevated pre-operative plasma ACTH. level
also fell in 12/21 patients undergoing resection of
bronchial carcinoma (Yalow et al., 1979)* Failure of
elevated levels to fall in 9/21 appeared to strengthen th
previous evidence that ectopic ACTH. may also arise from
lung tissue which has been damaged or which has undergone
precancerous change.
After an elevated ACTH. concentration has fallen to
normal following treatment, a subsequent rise may indicat
tumour recurrence and progression (Gropp et al., 1980).
However failure of plasma ACTH. to rise by no means rules
out the possibility of tumour recurrence (Hansen et al.,
1980b). Finally pre-operative ACTH. concentrations gave
no guide to prognosis in patients undergoing surgical
resection of lung cancer (Yalow et al., 1979)*
The finding of raised levels of circulating ACTH.
and related hormones in lung cancer patients is of
considerable research interest. However at present
measurement of these hormones, either individually or
collectively, is not likely to be of much value in the
assessment and management of the individual patient or




There is abundant evidence of a host defence against
tumours which involves the activity of lymphocytes and
macrophages. In lung cancer, tumour-associated antigens,
antibodies and circulating immune complexes have all been
described; lung cancer patients with active immunological
reactions to antigens survive longer than those without.
Our studies have shown a higher prevalence of abnormal
results in lung cancer patients than those found in controls.
In general, the abnormalities have been less prevalent
than those reported by other authors. This discrepancy
seems to arise from their selection of unsuitable controls.
Impairment of immunological tests is commoner in smokers,
in patients with benign pulmonary disease and in older
patients. Thus to assess the relevance of a particular
test in lung cancer patients who are usually middle-aged
or elderly, cigarette smokers and sufferers from chronic
bronchitis, controls matched for age, sex, smoking habit
and presence of benign pulmonary disease should be used.
This investigation has shown that abnormal immuno¬
logical responses do occur even in patients with operable
lung cancer. Recognition of new antigenic material (DNCB.)
is impaired suggesting that there is a defect in the
immunological surveillance mechanism. Moreover lymphocyte
transformation by PPD. but not by PHA. or PWM. was
depressed. This could be due to the action of PPD.
stimulated suppressor cells on other lymphocytes.
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Can specific autologous immunotherapy enhance the
elimination of residual tumour cells in patients who
have undergone resection of the bulk of the tumour? In
the pilot trial, intradermal injection of irradiated
autologous tumour cells and intradermal BCG. was followed
by increased tuberculin reactivity and leukocytosis in
the autograft group. This resulted in serious local
ulceration, especially in strong tuberculin reactors, but
there was no significant difference in clinical results
between the autograft and non-autograft groups of patients,
both of whom were treated with radiotherapy. In the
subsequent main trial, the overall effect of postoperative
serial percutaneous injections of autologous irradiated
tumour cells and BCG. was to produce a prolonged rise
in tuberculin reactivity but only a modest improvement
in clinical results. There was some evidence that this
treatment improved the survival and duration of freedom
from tumour recurrence of patients with stage I tumours
and those who became sensitised to DNCB. before operation.
Hence in these patients, specific autologous immunotherapy
may have a place as an adjuvant to surgery.
In an assessment of the value of measuring circulating
antigenic markers in the diagnosis of lung cancer, it was
found that the prevalences of elevated levels of both
ACTH. and CEA. in unselected lung cancer patients were
much lower than those found by some other authors. This
was due to the selection as a reference value of the
upper limit of values recorded from age and sex matched
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controls with benign pulmonary disease rather than that
of normal healthy controls. Levels of both of these
markers were higher in patients with extensive disease
and of ACTH. in patients with small cell carcinoma.
However the prevalence of elevated circulating antigenic
markers, either individually or in combination, was not
high enough for these measurements to be of value in the
screening of populations for lung cancer or its diagnosis
in patients. Where initial levels of these markers are
elevated, serial measurements may be of value in monitoring
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